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Abstract 
A computational model of thiopurine metabolism 
The thiopurines, azathioprine, mercaptopurine (MP) and thioguanine are used 
as immunosuppressants and in the treatment of leukaemia. These drugs 
undergo extensive metabolism to form their cytotoxic metabolites that correlate 
with drug efficacy and the likelihood of side effects.  Although these inexpensive 
drugs are effective in many patients, a deeper understanding of thiopurine 
metabolism would enable better individualisation of therapy resulting in 
increased efficacy and safety.  
A computational model of MP metabolism using data generated from 
mercaptopurine treated MOLT-4 (human T-ALL cell line) by a novel liquid 
chromatography mass spectrometry assay was built in CoPaSi. The model 
qualitatively reproduced published data about the effects of changes in 
thiopurine methyltransferase activity on MP metabolism. 
In vitro studies showed that high concentrations of allopurinol, a xanthine 
oxidase inhibitor, reduced the sensitivity of MOLT-4 cells to MP from 2.9 µM to 
43 µM (P<0.001), whereas lower concentrations of allopurinol slightly but not 
significantly increased the sensitivity of MOLT-4 cells to MP. 
Combination of MP and allopurinol treatment of MOLT-4 cells resulted in lower 
concentrations of thioguanine nucleotides and methylated thioinosine 
monophosphate metabolites compared to MP only treatment, as determined by 
liquid chromatography mass spectrometry.  
These data were used to extend the model of MP metabolism to test 
hypotheses that addition of allopurinol decreased methylated thioinosine 
monophosphate and increased the concentration of TGNs. The computational 
model suggested that the mechanism by which allopurinol interacts with MP 
metabolism is by inhibiting hypoxanthine guanine phosphoribosyl transferase 
resulting in altered levels of MeTIMP and TGNs.  
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Chapter 1. Introduction to thiopurines and systems biology 
1.1 Introduction 
Thiopurines were developed by Elion and Hitchings during the 1940’s and ‘50’s 
(Elion et al., 1988). Following observations that endogenous purines were 
essential to cell replication it was hoped purine analogues would interfere with 
endogenous purine metabolism and would lead to a reduction in replication of 
cancer cells (Elion et al., 1988). The thiopurines mercaptopurine (MP), 
azathioprine (AZA) and thioguanine (TG), are now used to treat paediatric 
leukaemia (Clinical Trial Service Unit) and autoimmune diseases such as 
inflammatory bowel disease (IBD) (Gleeson and Heneghan, 2011; Girardin et 
al., 2012; Bressler et al., 2015) and as immunosuppression after transplantation 
(Scheffert and Raza, 2014). They are pro-drugs which rely on a complex 
metabolism to produce their active metabolites; thioguanosine nucleotides 
(TGNs) incorporated into DNA and the thioguanosine mono, di and tri 
phosphates (TGMP, TGDP and TGTP). This metabolism shows variation 
between individuals, as does the efficacy. 
There is a variation in the efficacy of thiopurine treatment between patients; this 
is due to the variation in production of thiopurine metabolites. For example 
around 30% of Crohn’s Disease patients, a type of IBD (Cuffari et al., 1996b), 
do not respond to treatment with thiopurines, and this often corresponds with a 
low level of TGNs (Cuffari et al., 1996b; Wright et al., 2004; Osterman et al., 
2006). Other patients treated with thiopurines produce too many TGNs, 
frequently due to lack of the methylating enzyme thiopurine methyltransferase 
(TPMT) (Enzyme Commission (E.C.) 2.1.1.67), and experience complications 
including neutropenia, leukopenia and pancytopenia (Lennard et al., 1997). A 
further group of patients produce excessive amounts of methylated thiopurine 
metabolites, products of an alternative pathway of metabolism, and these have 
been linked to hepatotoxicity (Dubinsky et al., 2000; Derijks et al., 2004; 
Gardiner et al., 2008b). TGN concentration has also been shown to be 
important for predicting prognosis in leukaemia after MP treatment 
(Schmiegelow et al., 1995). 
Many clinical studies have found evidence of correlations between levels of 
thiopurine metabolites, which are linked to treatment efficacy, and the activities 
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and expression of various enzymes, mostly those involved in endogenous 
purine metabolism. There have also been cell-based studies seeking to provide 
more detailed mechanistic insights into variation in the production and effects of 
thiopurine metabolites. 
Systems biology approaches biological questions by examining whole systems 
in order to understand their structure and dynamics. This is in contrast to 
traditional biological approaches which focus in detail on individual components 
(Kitano, 2002b). One technique of systems biology is using detailed information 
on molecular mechanisms to build computational models (Wolkenhauer, 2014). 
This approach can enable an improved understanding of the relationships 
between system components and their emergent behaviours. 
The metabolism of thiopurines is a complicated but well-studied system. 
Despite over 60 years of investigation it is still impossible to predict fully which 
patients will benefit from what dose of thiopurine and in what combination with 
other drugs. It was envisaged that creating a computational dynamic model 
would allow insights to be gained about the combined effects of the many 
components of the metabolism of thiopurines that have previously been studied. 
1.1.2 Thiopurine structure 
The thiopurines are sulphur-substituted analogues to endogenous purines. AZA 
(6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine) and MP (3,7-dihydropurine-
6-thione) are analogues of hypoxanthine (HX) and TG (2-amino-3,7-
dihydropurine-6-thione) is an analogue of guanine (Figure 1.1 a and c). In all 
three drugs, the oxygen normally bonded to the 6-carbon atom is replaced by 
sulphur as indicated by the chemical names (Van Scoik et al., 1985). In addition 
AZA has an imidazole moiety attached to this sulphur (Figure 1.1b). AZA was 
developed shortly after MP. It was thought that the extra reaction removing the 
imidazole group from MP would allow for a steadier production of active 
metabolites over time. Early studies indicated that the addition of the imidazole 
group increased the therapeutic index of MP. 
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   a 
  b 
   c  
 
Figure 1.1 The chemical structure of a MP b AZA, showing the sulphur bonded to the 
position 6 carbon and c TG drawn in PubChem Sketcher version 2.4 
((https://pubchem.ncbi.nlm.nih.gov/edit2/index.html)) 
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1.1.3 Thiopurine metabolism 
The metabolism of thiopurines is a multi-step process that mirrors the reactions 
of endogenous purine recycling (Figure 1.2). 
AZA is first metabolised to MP by removal of the imidazole group by reaction 
with glutathione normally catalysed by glutathione-s-transferase (GST) (E.C. 
2.5.1.13), although around 1% of the reaction of glutathione and AZA is non-
enzymatic. There are various subtypes of GST, A1-1, A2-2 and M1-1 that are 
abundantly expressed in liver and highly active with respect to AZA. 
Homozygosity for the GST-M1 deletion is found in around 50% of the 
population. This mutation has been shown to reduce the efficacy of AZA by 
reducing the amount of TGNs produced (Stocco et al., 2014). Other allelic 
variants of GST have increased activity and can lead to adverse drug reactions 
(Zhang et al., 2010). 
MP and TG are both taken up into cell types by concentrative nucleoside 
transporters (CNT) 1,2 and 3 (Peng et al., 2008) and equilbrative nucleoside 
transporter 2 (ENT) (Fotoohi et al., 2006a; Nagai et al., 2007). MP may also be 
removed by multi-drug resistance protein 4 (MRP4) (Krishnamurthy et al., 
2008). The expression levels of these proteins have been shown to correlate 
with sensitivity of cells to thiopurines. 
MP and TG are both metabolised by hypoxanthine-guanine phosphoribosyl 
transferase (HGPRT, E.C. 2.4.2.8) to form their respective mono phosphate 
nucleosides, thioinosine monophosphate (TIMP) and TGMP, by addition of 
ribose sugar and a phosphate group. Cells which lack HGPRT are resistant to 
thiopurine drugs (Brockman et al., 1960). However normal variation in activity of 
HGPRT does not appear to determine differences in MP response (Pieters et 
al., 1992; Lennard et al., 1993). 
TIMP is further metabolised to produce thioxanthosine monophosphate (TXMP) 
by nicotinamide adenine dinucleotide (NAD) dependent oxidation by inosine 
monophosphate dehydrogenase (IMPDH, E.C. 1.1.1.205). IMPDH activity has 
been observed to correlate positively with methyl thioinosine monophosphate 
(meTIMP)/TGN ratio (Haglund et al., 2011). IMPDH activity has been shown to 
increase in vitro after TG treatment (Vethe et al., 2008), possibly due to 
increased demand for endogenous guanosine nucleotides.
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Figure 1.2 The metabolism of AZA, TG and MP. Including the metabolism of AZA to MP using glutathione catalysed by GST(blue arrow), uptake by 
equilbrative and concentrative nucleotide transporters (ENTs and CNTs) (black arrows), metabolism by various enzymes hypoxanthine-guanine 
phosphoribosyl transferase (HGPRT), xanthine oxidase (XO), inosine monophosphate dehydrogenase (IMPDH), GMP synthase (GMPS) and 
thiopurine methyl transferase (TPMT), (blue arrows) and excretion of thio uric acid, (black arrow). Cytotoxic effects via incorporation into DNA, 
disruption of cell signalling and inhibition of de novo purine synthesis (red arrows), and the site of action of XO inhibitors (*). 
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TXMP is aminated to TGMP by guanosine monophosphate synthase (GMPS, 
E.C. 6.3.5.2), although this reaction is less favourable than that of endogenous 
xanthosine monophosphate (XMP) (Spector, 1975). 
TGMP is acted upon by nucleotide kinases to form the other TGNs TGDP and 
TGTP. TGTP is further processed to form deoxyTGTP which may be 
incorporated into DNA. 
Thiopurine metabolites are methylated by TPMT. These reactions form the 
methylated metabolites meTIMP, methyl thioguanosine monophosphate 
(meTGMP) and methyl mercaptopurine (me MP) (Krynetski et al., 1995). There 
has been extensive research into the activity and genetics of TPMT. A tri-modal 
distribution of activities has been discovered. Around 88% of the population has 
a high (normal) TPMT activity, 11% of the population has half or less activity 
and less than 1% of the population no TPMT activity (Weinshilboum and 
Sladek, 1980). This has been shown to be a result of a monogenic inheritance 
of TMPT in a co-dominant fashion. A low TPMT activity has been shown to 
increase the risk of developing adverse reactions, such as neutropenia, to 
thiopurines at the standard dose (Coulthard et al., 2002). This is due to patients 
with low TPMT activity producing more of the cytotoxic TGNs and less of the 
largely-inactive methylated metabolites. There are around 30 genetic variants 
which lead to a reduction in, or absence of TPMT activity and increased TGNs 
from standard thiopurine doses (Appell et al., 2013; Hlavaty et al., 2013). In 
Caucasians the most common single nucleotide polymorphisms are TPMT*3A 
and TPMT*3C (Serpe et al., 2009). Structural analysis of some of the mutant 
alleles has shown that some SNPs produce TPMT proteins which are less 
stable than wild type protein (Feng et al., 2010). Treatment with MP has also 
been shown to decrease TPMT expression via a variable number tandem 
repeat in the TPMT promoter (Alves et al., 2001; Kotur et al., 2012). There have 
also been cases of patients with extremely high TPMT activity who have either 
not responded to thiopurine treatment (Ansari et al., 2002) or suffered side 
effects due to increased methylated metabolite levels (Seinen et al., 2013b). 
Pre-treatment genetic testing for TPMT is now recommended (Sanderson et al., 
2004). If a patient is found to be homozygous or heterozygous for one of the 
known TPMT reduced-activity alleles (Appell et al., 2013), then either up to a 10 
fold reduction of thiopurine dose is recommended or another drug should be 
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prescribed (Relling et al., 2011). In the case of leukaemia the recommended 
dose of MP is reduced from 60 or 75 mg/m2 to 6 or 7.5 mg/m2 depending on the 
age of patient and the aggressiveness of their disease. In IBD dosage of 
thiopurine is often determined by the level of TGNs measured, patients with low 
TPMT activity tend to receive around half the dose of AZA than those with 
normal TPMT activity to achieve TGNs over 235 pmol/8 x 10(8) RBCs from 0.9 
mg/kg/day to 1.8 mg/kg/day (Gardiner et al., 2008a). Differences in TPMT 
accounts for about half the variability in response to thiopurine drugs and in 
some diseases such as in rheumatoid arthritis it has been suggested that it may 
not be cost effective to determine TPMT activity prior to treatment with 
thiopurines (Booth et al., 2011, Pavlovic and Zukic, 2010). 
 MP is also metabolised by xanthine oxidase (XO, E.C. 1.17.1.4). This enzyme 
converts MP to thioxanthine (TX) and TX to thiouric acid (TUA) which is 
excreted in urine (Kudo et al., 2010) (Atkinson et al., 1965). XO competes with 
HGPRT for MP (Kalra et al., 2007). This competition may be clinically significant 
by reducing the efficacy of MP and AZA in patients with high XO activity (Wong 
et al., 2007).  
Thioinosine triphosphate (TITP) is metabolised by inosine triphosphate 
phosphatase (ITPA, E.C. 3.6.1.19) to form TIMP (Bakker et al., 2011). ITPA 
activity ensures that endogenous inosine triphosphate (ITP) is kept to a 
minimum to reduce the risk of it being inappropriately incorporated into DNA. 
Low ITPA activity has been shown to increase the ratio of methylated 
metabolites to TGNs which may lead to decreased efficacy of thiopurines (de 
Beaumais et al., 2011). 
1.1.4 Mechanisms of thiopurine cytotoxicity 
It has been demonstrated that there are a variety of causes of thiopurine 
cytotoxicity; most of these are apparently caused by TGNs. A major cause of 
cytotoxicity of thiopurines is the conversion of TGNs to deoxyTGNs and 
incorporation of these into DNA. It has been shown that pharmacologically 
inhibiting DNA synthesis, and therefore preventing incorporation of TGNs in 
DNA reduces the efficacy of thiopurines (Lee and Sartorelli, 1981). TGNs 
incorporated into DNA create structural DNA lesions that may incorrectly base 
pair with thymine (Bohon and de los Santos, 2003). This is due to the altered 
hydrogen bonding properties of the thiol group compared to the endogenous 
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oxygen (Figure 1.1). This allows only two hydrogen bonds to form instead of the 
usual three formed by endogenous guanine allowing pairing with thymidine. 
These lesions trigger mismatch repair (MMR) systems which begin futile repair 
attempts and result in apoptosis being triggered (Swann et al., 1996, Karran, 
2006). MMR-deficient cells are also susceptible to killing by thiopurine drugs. 
The involvement of homologous recombination (HR) in the toxic effects of 
thiopurine drugs has been shown. Rajesh et al. (2011) showed that cells with 
deletion of Rad 51d, needed for HR, are hypersensitive to TG; this is rescued 
by co-deletion of Mlh1, part of the MMR pathway. However these cells show 
increased chromosomal instability, suggesting that thiopurines are still 
incorporated into DNA. Thiopurine drugs can selectively kill BRCA-2-defective 
tumours, BRCA-2 protein is part of the HR pathway (Issaeva et al., 2010).  
The incorporation of methyl TGNs into DNA has been demonstrated to block 
transcription, which may also contribute to cytotoxicity of thiopurines (Changjun 
et al., 2012). Incorporation of TGNs and methylTGNs into RNA may reduce the 
rate and accuracy of transcription, and may reduce cell viability (You et al., 
2012). 
TGNs do not act only via their incorporation into nucleic acids but also interfere 
with G-protein signalling. Studies have shown that the interaction of TGTP with 
the Rac/Vav signalling pathway, in place of endogenous GTP is cytotoxic (Tiede 
et al., 2003). CD28 activation of T-cells usually results in pro-survival signals via 
the GTP transfer between Vav and Rac, activating Rac which then acts via the 
MEKK pathway. However if TGTP binds to Rac it does not activate Rac and so 
apoptotic signals prevail leading to cell death (Heo and Hong, 2010). 
As well as the various cytotoxic effects of TGNs, methylated thiopurine 
metabolites have cytotoxic effects. meTIMP inhibits de novo purine synthesis 
(DNPS) by inhibiting phosphoribosylpyrophosphate amidotransferase (E.C. 
2.4.2.14) (Tay et al., 1969; Benson et al., 1970; Mario et al., 1993). This 
reduces the availability of endogenous purines, which are essential to cell 
growth and survival. Also the reduction in endogenous purines may amplify the 
influence of the thiopurines by increasing the substitution of thiopurines for 
endogenous purines in processes such as DNA production. This process 
contributes to the sensitivity of cells to MP but not TG (Dervieux et al., 2001).  
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Methyl thio-adenosine phosphorylase (MTAP, E.C. 2.4.2.28) is an enzyme of 
methionine and adenosine salvage. MTAP-deficient cells are more sensitive to 
thiopurine drugs (Coulthard et al., 2011). Its deletion increases cellular reliance 
on DNPS probably due to a build-up of methyl thio-adenosine which is a 
feedback inhibitor of adenine, methionine and spermine recycling pathways 
(Basu et al., 2011). DNPS is inhibited by methylated thiopurine metabolites. 
Also increased MTAP activity decreases TPMT activity and methylated 
metabolites; in spite of this MTAP negative cells are more sensitive to MP than 
MTAP positive cells (Coulthard et al., 2011). Finally, thiopurine treatment has 
been shown to alter DNA methylation in vitro. This may cause cytotoxicity, but 
this does not appear to depend on TPMT activity (Hogarth et al., 2008; Wang 
and Wang, 2010a; Yuan et al., 2011). 
1.1.5 Current Clinical use 
MP and occasionally TG are used in the treatment of paediatric T-lineage acute 
lymphocytic leukaemia (T-ALL). The incidence of ALL is 1.36 per 100 000 in the 
United States of America for 1975-2011 (Surveillance). The intermediate 
recommendations for treatment of T-ALL in children under 10 without high risk 
factor between UKALL 2003 and UKALL 2011 trials suggested the use of 75 
mg/m2 from week 5 of induction treatment in combination with dexamethasone, 
vincristine, pegylated asparginase and methotrexate, the same dose of MP is 
used during interim maintenance phase in combination with the other drugs 
mentioned above and danorubicin, followed by a reduction to 60 mg/m2  of MP 
in combination with other drugs during delayed intensification, MP is increased 
back to 75 mg/m2 for 2 or three years of maintenance therapy, again in 
combination with other drugs. It is recommended that patients homozygous for 
TPMT low activity alleles are given 10% of the normal dose, 6 or 7.5 mg/m2 
(Clinical Trial Service Unit) or 10% of the normal dose, 7.5 mg/ m2, on alternate 
days instead of daily (Lennard et al., 1997). The same doses of MP are 
recommended for higher risk patients but with different combinations of other 
drugs (Clinical Trial Service Unit). It has also been suggested that TG may 
replace MP for patients lacking TPMT, as TG metabolism by TPMT is less 
critical to TG. However there is an increased risk of veno-occlusive disease 
when using TG (Sati et al., 1982). Higher thiopurine doses have been 
associated with improved outcome but also with secondary malignant neoplasm 
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(Schmiegelow et al., 2009). Given that too little thiopurine or too much have 
been shown to have adverse outcomes it is important that the dose of these 
drugs is optimised for individual patients. 
AZA, and more occasionally TG and MP are used in the treatment of 
inflammatory conditions such as IBD. IBD is a group of conditions; ulcerative 
colitis, inflammation of the colon, and Crohn’s disease, inflammation of the 
small intestine. Both are due to an inappropriate activation of the mucosal 
immune system damaging the gut. The incidence of Crohn’s disease in Europe 
varies between countries from 0.87 to 9.8 cases per 100 000 people (Loftus, 
2004). Ulcerative colitis has a slightly higher incidence between 1.5 and 20.3 
cases per 100 000 (Loftus, 2004). IBD is treated with a combination of drugs 
and surgery. Drugs used include infliximab, an anti-tumour necrosis factor 
(TNF) alpha monoclonal antibody, corticosteroids and immunomodulators 
including methotrexate and the thiopurines, in particular AZA (Bressler et al., 
2015). Thiopurines are often used as steroid-sparing agents, this reduces dose 
of corticosteroid used and therefore the harmful side effects such as weight gain 
and growth stunting are minimised. Newer drugs such as Infliximab are mono-
clonal antibodies targeting TNF to reduce inflammation. Although these drugs 
become effective more rapidly than thiopurines they must be administered 
either intra-venously or sub-cutaneously, not orally, making them less 
convenient and some studies have associated them with an increased risk of 
infection. 
There have been several strategies developed to improve the response of IBD 
patients to thiopurines, reducing or removing the necessity for them to be 
treated with other drugs or surgery. One strategy is to combine AZA with 
allopurinol, this is discussed in detail later. Another strategy is to administer the 
same daily dose of AZA, MP or TG split into two doses to be taken morning and 
evening. Splitting the dose of AZA or MP into two daily doses rather than one 
has been shown to maintain therapeutic TGN levels whilst reducing levels of 
methylated metabolites (Shih et al., 2012). It is as yet unclear why there is this 
effect on the relative amounts of different metabolites of thiopurine metabolites. 
1.1.6 Optimisation of thiopurine therapy using allopurinol 
Both TGNs and methylated thiopurine metabolites contribute to the cytotoxicity 
of thiopurines and their side effects. However whilst TGN levels correlate most 
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strongly with efficacy, methylated metabolite levels correlate mostly with toxic 
side effects, particularly hepatotoxicity (Dubinsky et al., 2002; Derijks et al., 
2004; Gardiner et al., 2008b). In some patients who do not respond to AZA or 
MP, dose escalation results in the same TGN levels but higher methylated 
metabolite levels and side effects, these patients are referred to as hyper-
methylators or shunters (Gardiner et al., 2008b) (Ansari et al., 2002; Dubinsky 
et al., 2002). It is important to note that although a correlation between 
hypermethylation and hepatoxicity has been shown a mechanistic explanation 
has not yet been found. It has been suggested that hyper-methylation is not 
necessarily caused by higher than usual TPMT activity (Seinen et al., 2013b). 
Recently a reduced dose of AZA or occasionally MP combined with low dose 
allopurinol has been shown to reduce the level of methylated metabolites whilst 
maintaining or increasing TGNs in erythrocytes (RBCs) to desirable levels, from 
levels of methylated metabolites over 5,700 pmoles/8 x 108 RBCs and under 
235 pmoles/ 8 x 108 RBCs of TGNs (Sparrow et al., 2005; Leung et al., 2009; 
Schmiegelow et al., 2010; Brackett et al., 2014). 
Allopurinol is a HX analogue that, along with its longer lasting metabolite 
oxypurinol acts as an XO inhibitor (Elion, 1966; Elion, 1989), (Hande et al., 
1978). It is used to reduce uric acid (UA) concentrations in gout (Ts'ai-Fan and 
Gutman, 1964) (Elion, 1989). It was initially developed with the assumption that 
by blocking the excretion of thiopurines their efficacy would be increased (Elion 
et al., 1988). Initial trials of the combination of allopurinol with thiopurines 
showed increased toxicity in humans rather than the hoped for increase in 
therapeutic effects. This led to allopurinol being used only in the treatment of 
gout and high urate for several decades (Coffey et al., 1972; Walker et al., 
1973; Tterlikkis et al., 1983) (Tterlikkis et al., 1983; Elion et al., 1988) and it was 
recommended that if allopurinol treatment for high urate levels was needed in 
combination with immunosuppression thiopurines should be avoided or used at 
a reduced level. This approach is still recommended by some clinicians 
(Scheffert and Raza, 2014). It was not until the 2000’s that a low dose AZA and 
allopurinol regime has been recommended in the treatment of IBD (Sparrow et 
al., 2005), this followed use of this drug combination in renal transplant (Chocair 
et al., 1993). This regime is normally recommended for patients with a high 
methylated metabolites and low TGNs which do not respond to dose increases. 
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The dose of AZA is reduced to between half and one quarter of its previous 
dose, for example in the initial Sparrow study in 2005 the average AZA dose 
dropped from 188 mg/day to 88 mg/day; this was combined with 100 mg of 
allopurinol, instead of the standard gout treatment dose of 300 mg. This has 
been shown to increase TGNs to above 235 pmoles/8 x 108 RBCs, a 
therapeutic level, and reduce the amount of methylated metabolites. This 
alteration in metabolite levels was shown to be effective at decreasing the need 
for steroids with minimal side effects such as leukopenia (Seinen et al., 2013a). 
The effect on the ratio of methylated metabolites/TGNs is unexpected as the 
inhibition of XO, the alternative metabolic pathway for MP, would be expected to 
increase the concentration of all MP metabolites other than TX and TUA. 
It has been suggested that allopurinol increases the concentration of TX and 
that this inhibits TPMT (Blakera et al., 2012), decreasing the relative 
concentration of methylated metabolites produced by TPMT. Allopurinol itself 
does not inhibit TPMT (Seinen et al., 2013a). Chronic treatment with allopurinol 
and AZA produces an increased HGPRT activity in RBCs (Seinen et al., 2011). 
XO also has aldehyde oxidase effects and allopurinol also inhibits aldehyde 
oxidase (Krinetsky et al., 1972), a closely related enzyme and affect the reactive 
oxygen species (ROS) production by both enzymes. It has been suggested that 
the reduced adverse events observed in patients on the combination of AZA 
and allopurinol may be due to a reduction in cellular damage by ROS and it has 
been shown that allopurinol reduces AZA associated ROS in rat hepatocytes (Al 
Maruf et al., 2014). It may be that ROS are particularly important to the cytotoxic 
effects of thiopurines on DNA via oxidation of incorporated TGNs (Brem and 
Karran, 2012) and that by reducing the amount of ROS excess DNA damage is 
prevented. 
Clearly it is important to understand the mechanistic basis of interaction 
between thiopurine metabolism and allopurinol in order to improve the clinical 
use of this drug combination. 
1.1.7 Measurement of thiopurine metabolites 
The metabolism of thiopurines (Figure 1.2) relies on several enzymes which 
may vary in activity between individuals. This variation has a clinical relevance. 
Measurements of TGNs and meTIMP are normally made in RBCs, an abundant 
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cell type but not the cell type assumed to be the target of thiopurine drugs; 
RBCs also lack the necessary enzymes for production of TGNs and, therefore, 
must accumulate TGNs released from other cell types. Despite the limitations of 
assaying thiopurine metabolites in RBCs, a correlation has been repeatedly 
shown between concentration of TGNs and outcome of treatment (Dubinsky et 
al., 2000; Cuffari et al., 2001; Wright et al., 2004; Ooi et al., 2007). 
Measurements of methyl mercaptopurine riboside (me MPR), used as 
representative of methylated inosinic metabolites, indicate the likelihood of 
hepatotoxicity (Dubinsky et al., 2000; Dubinsky et al., 2002; Derijks et al., 2004; 
Gardiner et al., 2008b). However, large scale analyses of the utility of thiopurine 
metabolite measurements do not all find them to be useful (Konidari et al., 
2014). Many do but others do not (Osterman et al., 2006; Ooi et al., 2007; 
Moreau et al., 2014).  
There is a method-dependent variation in thiopurine metabolite levels measured 
using two common methods for TGN measurement (Shipkova et al., 2003), with 
a 2.6 fold difference between measurements made by the Lennard method 
(Lennard, 1987), which relies on phenyl mercury adduct formation and sulphuric 
acid hydrolysis to extract metabolites, and the Dervieux method (Dervieux and 
Boulieu, 1998c) which uses perchloric acid and dithiothreitol (DTT). Although 
Shipkova also states that this difference can be reduced to 1.4 fold by using 
perchloric acid in the Lennard method rather than the previously described 
sulphuric acid (Shipkova et al., 2003). The different processing strategies used 
by each method cause a difference in the hydrolysis of TGNs to TG and 
therefore the reported metabolite levels.  
It has been shown that meTIMP and me MPR become 4-amino-5-
(methylthio)carbonyl imidazole, which is detected, after preparation by 
Dervieux’s acid hydrolysis method  (Dervieux and Boulieu, 1998b; Dervieux et 
al., 2001). This may make comparison between metabolite levels difficult. 
Despite these differences in processing, some studies of the correlation 
between reported metabolite levels and outcome shows that TGN measurement 
correlates with remission in IBD and leukaemia, indicating that metabolite 
measurement is a useful clinical tool (Schmiegelow et al., 1995; Osterman et 
al., 2006; Ooi et al., 2007). A more direct measurement of thiopurine 
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metabolites in more-clinically-relevant cell types may prove a more sensitive 
indicator of clinical efficacy.  
1.1.8 Systems biology 
Systems biology is an increasingly popular approach to studying biology. 
Traditional biochemical and genetics approaches have focussed on detailed 
studies of individual components of biological systems, for example a protein. In 
contrast systems biology as described by Hood (Ideker et al., 2001), seeks a 
more integrated picture of an organism as a whole, “it investigates the 
behaviour and relationships of all of the elements in a particular biological 
system while it is functioning.” (Ideker et al., 2001). It is a way of understanding 
and utilising the large quantities of complex data, such as genome wide 
association studies and proteomics studies, becoming available to biologists. 
Two complementary approaches are taken by systems biologists. The top-down 
approach uses large datasets to investigate the interactions of components of 
biological systems often without initial hypotheses. The bottom-up approach 
explores current hypotheses about a system. It integrates previous data, often 
from several sources along with new data to validate or refute old ideas and 
develop new ones about a biological system. Systems biology uses theories 
and techniques, such as systems control theory, from engineering to carry out 
these approaches. 
A bottom up approach, computational dynamic modelling allows biological 
systems to be explored with in silico experiments, “providing predictions to be 
tested by in vivo and in vitro studies. to predict the dynamics of systems so that 
the validity of the underlying assumptions can be tested” (Kitano, 2002a). 
Mathematical modelling of biological systems, reducing them to a set of 
mathematical equations that approximates their behaviour to aid description 
and understanding, has been used for many decades. It has been used in 
enzyme biochemistry and pharmacology, for example Michaelis-Menten kinetics 
(Michaelis and Menten, 1913) approximated enzyme substrate binding with 
their equation enabling the study of reaction kinetics. However with the 
invention of computers in the 1950’s larger, more complex sets of equations 
could be solved and analysed. For example Turing’s description of morphogen 
activity (Turing, 1952) during development. The increasing power of computers 
over the last few decades is a key factor that has led to an explosion in the 
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number of computational models of biological systems. The BioModels 
database website listed 530 curated and 655 non-curated models in September 
2014 that have been manually created plus over 100 000 created automatically 
from online databases (http://www.ebi.ac.uk/biomodels-main/#; Chen et al., 
2010). These models have contributed to a fuller understanding of the emergent 
properties of networks and their motifs. For example feedback loops give rise to 
certain behaviours such as signal amplification, switching or oscillations as 
described by (Alon, 2007).  
Model building is often part of a cycle of modelling and experimentation in which 
in vitro, in vivo and in silico stages validate and inform each other. Modelling 
suggests future experiments and experiments provide data for model validation 
and expansion.  
Dynamic computational models have been successfully used describe 
endogenous purine metabolism (Curto et al., 1997; Curto et al., 1998a; Curto et 
al., 1998b) and the effects of pharmacological inhibition of IMPDH on 
concentrations of endogenous purines (Thomas, 2010). Curto et al. used their 
model to explore possible therapeutic options for enzyme deficiencies of purine 
metabolism (Curto et al., 1998a). 
A previously published study of the cytotoxic effects of TGN incorporation used 
dynamic modelling of the cell cycle and large scale gene expression analysis to 
examine the mechanisms of loss of sensitivity of cell culture cell lines to MP 
(Panetta et al., 2006). The process of cell cycle arrest and apoptosis was 
modelled and data from sensitive and insensitive cells was used to estimate the 
kinetic constants of the model. Comparison of these constants enabled 
differences in response to TGN incorporation to be analysed showing that 
differences in the progress through the cell cycle were important. This result 
was confirmed by gene expression differences in the sensitive and resistant 
cells in proteins involved in the regulation of the cell cycle. 
The pharmacokinetics and metabolism of thiopurines in patients have also been 
analysed using computational modelling (Fransson et al., 2006; Fransson et al., 
2007). However the study was inconclusive, the model had a limited ability to fit 
data from patients about the changing concentrations in RBCs of meTIMP and 
TGNs in patients newly treated with AZA. The relatively small number of 
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metabolites analysed compared to the complexity of thiopurine metabolism 
along with the complications of metabolism in different cells and the exchange 
of metabolites between cell types and extracellular compartments meant that 
this model was unsuccessful.  
Systems biology is also associated with a move towards personalising 
medicine. This includes better understanding the implications of genomic, and 
other large scale data about patients and also by modelling the course of 
diseases and the effects of pharmacological interventions. This is becoming 
known as “4P medicine” standing for predictive, personalised, preventative and 
participatory medicine, and aims to improve healthcare for individuals and 
eventually to reduce costs by making medicine more proactive (Hood and 
Friend, 2011). An example of this is a computational model of apoptosis built 
using data from cell lines (Huber et al., 2007) that has been applied to samples 
from patients with colon cancer. It was shown to predict their response to 
treatment (Hector et al., 2012). This may, soon, be used clinically to direct 
treatment.  
The metabolism of thiopurines and their downstream effects are complex and, 
despite long term in vivo and in vitro study, are still not fully understood. This 
lack of understanding means that not all patients can benefit from treatment 
with thiopurine drugs. The purpose of this project was to complement new and 
existing in vitro studies with in silico studies using systems biology techniques. It 
was envisaged that by integrating previous knowledge of the mechanisms of 
thiopurine metabolism into a computational model the interactions between 
different parts of thiopurine metabolism and their relative influence on the 
production of thiopurine metabolites would be better understood. This model 
could be used to predict the effects of altering thiopurine metabolism on the 
production of cytotoxic metabolites, for example exploring the effects of differing 
enzyme activities and the interactions of thiopurines with other drugs. 
Increasing understanding of thiopurine metabolism could eventually lead to 
improved treatment of patients by taking into account their ability to metabolise 
thiopurine drugs. This personalisation of drug dosage would improve the quality 
of life of patients, and reduce the cost of adverse drug reactions to the 
healthcare system.  
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1.1.9 Outlook 
The complexity discussed in the section on thiopurine metabolism particularly, 
the unexpected and unexplained effects of the combination of allopurinol with 
AZA or MP indicates the need for a computational modelling approach to 
understanding thiopurine metabolism. The previous successful use of 
computational modelling to understand the effects of thiopurines on cell survival 
(Panetta et al., 2006) and the analysis of purine metabolism (Curto et al., 1997; 
Curto et al., 1998a; Curto et al., 1998b; Thomas, 2010) provided confidence 
that informing dynamic modelling with in vitro data would be likely to be a 
successful tool for examining thiopurine metabolism. However a previous study 
attempting to model thiopurine metabolism in patients showed the limits of a 
computational modelling approach (Fransson et al., 2006; Fransson et al., 
2007). This model was unable to replicate data about whole body thiopurine 
metabolism. This was largely due to the fact that data was limited to one cell 
type and only two thiopurine metabolites. Given that the model was attempting 
to replicate the effects of reactions that include many other metabolites and 
their transport between many cell types, these data were inadequate. A 
dynamic model of thiopurine metabolism in cultured cells would be more likely 
to provide a tractable problem as it has a more limited set of transport reactions 
and is more amenable to the generation of experimental data on metabolite 
levels for validating the model. It is also the case that MP may provide a useful 
model for thiopurine metabolism in general. The metabolism of MP is the same 
as that of AZA except for the production of MP from AZA. As the activation of 
AZA is largely hepatic, intestinal and extra-cellular it would be difficult to study in 
a cell culture system of only one cell type.TG is less commonly used than MP 
and therefore is of less clinical relevance, also the metabolism of TG lacks 
several of the steps of MP metabolism allowing less scope for study. For this 
reason MP has been studied most extensively during this project. 
1.1.10 Aims 
1. To build a dynamic computational model of in vitro thiopurine metabolism, using 
MP as an example 
2. To generate data on MP metabolites in cultured cells to facilitate model building 
and validation 
3. To assess the cellular effects of allopurinol, alone and with MP in vitro 
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4. To use the model to assess the possible mechanisms of interaction of MP 
metabolism and allopurinol  
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Chapter 2. Cytotoxicity of thiopurines and XO inhibitors 
2.1 Introduction 
The aim of this project was to produce a computational model of thiopurine 
metabolism to predict the production of different toxic metabolites and to 
elucidate the relationship between metabolites and mechanisms of cell death. 
Prior to producing data in cultured cells to inform the model it was necessary to 
determine that the cell line used was sensitive to MP, the drug whose 
metabolism would be modelled, and also to determine if allopurinol, a XO 
inhibitor relevant to thiopurine metabolism, caused cytotoxicity alone or in 
combination with MP. To this end cell viability was measured, after treatment 
with the drugs, by the methyl tetrazolium sulphate (MTS) assay (Barltrop and 
Owen, 1991).  
2.1.2 Utility of cell culture studies in the investigation of thiopurine drugs 
Many studies have utilised in vitro cell culture to elucidate the effects and the 
metabolism of the thiopurine drugs including effects of various enzymes MTAP 
(Coulthard et al., 2011), IMPDH (Yamada et al., 1990; Vethe et al., 2008) and in 
particular the clinically-relevant enzyme TPMT  (Dervieux et al., 2001; Coulthard 
et al., 2002; Misdaq et al., 2012)  on the sensitivity to AZA, MP, TG and their 
metabolites (Mario et al., 1993; Kalra et al., 2007). Studies of the downstream 
effects of various metabolites using cultured cells have suggested possible 
mechanisms by which the thiopurine metabolites cause cytotoxicity (Krynetski 
et al., 2001; Hogarth et al., 2008; Heo and Hong, 2010; Rajesh et al., 2011) and 
by which cells may develop resistance (Fotoohi et al., 2006b; Panetta et al., 
2006). One of these studies used a combination of in vitro studies and in silico 
modelling to enhance the understanding of the development of thiopurine 
resistance (Panetta et al., 2006). The computational model in this study 
suggested that differences in the process by which cells enter apoptosis may be 
responsible for differences in sensitivity to MP, this was confirmed by 
differences in expression of genes involved in apoptosis between sensitive and 
resistant cells. 
Cell culture experiments allow better controlled experiments using specific cell 
types than in vivo studies, as factors such as genetic background, and drug 
delivery time cannot be controlled with in vivo studies. However, in vitro studies 
allow only limited conclusions to be drawn about the metabolism of drugs in 
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patients as other factors such as hormones, blood circulation and metabolism 
by multiple cell types may be important. 
2.1.3 Thiopurine drug metabolism by T-ALL derived cell lines 
For these experiments MOLT-4 and Jurkat cell lines were used; these are both 
lymphocyte-derived cell lines from patients with T-ALL. T- ALL cells are 
considered to have the ability to metabolise thiopurine drugs fully (Figure 1.2). 
Thiopurine drugs are metabolised by XO. MP is metabolised by XO, first to TX 
then to TUA. This metabolism has been confirmed to occur in Jurkat cell lysates 
(Kalra et al., 2007). It was therefore assumed in this project that MOLT-4 cells, 
a cell line of similar origin, would also show this part of the metabolism. MOLT-4 
cells have IMPDH activity (Yamada et al., 1990; Vethe et al., 2008) and can 
therefore metabolise TIMP to TXMP. The action of HGPRT, IMPDH, GMPS and 
XO in MOLT-4 cells is further supported by the fact that, after incubation with 
MP, the metabolites TIMP, TXMP, TGMP and TUA or TX are all detectable in 
MOLT-4 cells (Zimm et al., 1985). It has also been shown that MOLT-4 cells are 
able to incorporate TGN into DNA after incubation with MP and that they also 
produce meTIMP showing TPMT activity (Bökkerink et al., 1993). The 
metabolism of thiopurine drug metabolites by TPMT has been shown to occur in 
CCRF-CEM and Jurkat cells lines (Dervieux et al., 2001), both of which are T-
ALL cell lines suggesting that T-ALL cell lines can be used to assess this aspect 
of thiopurine metabolism.  
The aim of therapy with thiopurine drugs is to reduce the number of 
lymphocytes in autoimmune diseases or the number of leukemic blast cells in T-
ALL. As MOLT-4 and Jurkat cells metabolise thiopurine drugs to their cytotoxic 
metabolites and are from a clinically-relevant cell type, these appear to be 
suitable models to use to generate data for a model of thiopurine metabolism. 
However MOLT-4 cells are tetraploid therefore their incorporation of TGNs into 
DNA, and its cytotoxic effects, may differ from normal diploid cells due to the 
difference in total DNA content. This difference must be borne in mind when 
drawing conclusions about the effects of thiopurines on cells resulting from the 
incorporation of TGNs into DNA from studies using MOLT-4 cells. 
2.1.4 XO inhibitors 
The aim of this project was to investigate the interaction between allopurinol 
and thiopurines experimentally in cultured cells and using a computational 
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model. The objective of these studies was to explore mechanisms by which 
allopurinol may modulate the effect of thiopurines in patients. Therefore, it was 
necessary to assess the cytotoxicity of allopurinol alone and in combination with 
MP. 
Although it is more common to combine AZA with allopurinol clinically, MP is an 
activated metabolite of AZA and offered a simpler system to study the effects of 
allopurinol on thiopurine metabolites. Furthermore, the clinical effect of MP with 
allopurinol was shown to be similar to that seen with AZA (Brackett et al., 2014).  
In addition to allopurinol the cytotoxicity of febuxostat and oxypurinol was 
assessed. These are alternative XO inhibitors; oxypurinol is a metabolite of 
allopurinol but febuxostat is not a purine analogue. It may be useful to compare 
the actions of these different types of XO inhibitor to assess which effects stem 
from the fact that allopurinol mimics HX and which effects are purely due to XO 
inhibition. 
2.1.5 Aims 
1. To confirm the sensitivity to thiopurine drugs of MP and AZA in MOLT-4 and 
Jurkat cell lines using the MTS assay.  
2. To assess the possible cytotoxic effects of allopurinol, its active metabolite 
oxypurinol and febuxostat in the same cell lines alone and in combination 
with MP, using the MTS assay.  
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2.2 Methods 
2.2.1 Cell lines 
Three cell lines were used throughout this project; all are T-ALL derived cell 
lines. Two were derived from Jurkat cells, a pseudo-diploid cell line expressing 
the human T cell antigen from the peripheral blood of a 14-year old male 
patient. Jurkat-MTAP-/-(Clontech™), expresses wild-type TPMT, and is MMR 
negative and MTAP deficient. Jurkat-MTAP+/+ are Jurkat-MTAP-/- cells stably 
transfected with MTAP cDNA under the control of a tetracycline promoter, 
previously engineered by Dr. Sally Coulthard. The third cell line was MOLT-4, 
derived from a 19 year old T-ALL patient after drug treatment and relapse. 
MOLT-4 cells are hyper-tetraploid, express MTAP and wild type TPMT but lack 
expression of p53. As previously discussed tetraploidy may affect the response 
of MOLT-4 cells to thiopurines due to altered DNA content. 
Jurkat-derived cell lines were grown in Roswell Park Memorial Institute (RPMI) 
medium containing 10% dialysed foetal calf serum (Cambrex™) and 500µg/ml 
Geneticin® (GIBCO-BRI but with the addition of 1 mg/ml Hygromycin B 
(Invitrogen™) for Jurkat-MTAP+/+ cells. Expression of MTAP was induced by 
the addition of 2 mg/ml Doxycycline to Jurkat-MTAP+/+ and as a negative control 
the same drug was added to the Jurkat-MTAP-/- cells.  MOLT-4 cells were 
grown in RPMI with 10% normal foetal calf serum (Cambrex™) and no other 
drugs. All cells were maintained in an incubator at 37˚C and 5% CO2. All cell 
lines have a doubling time of approximately 24 hours. Cells were maintained at 
a density of between 1x105 and 2x106/mL. 
2.2.2 MTS cell growth assay 
To measure the proportion of viable cells in drug sensitivity assays, a 96-well 
plate format MTS assay, CellTiter 96® Aqueous One Solution Cell Proliferation 
Assay (Promega, Southampton, United Kingdom), was used.  This is a 
colorimetric assay which relies on the ability of NAD(P)H oxidoreductases in 
viable cells to reduce the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium to a soluble formazan 
product detectable at 490-560nm (Barltrop and Owen, 1991). To perform this 
assay, 25 µL of MTS reagent was added to wells of a 96 well plate containing 
200 µL of either blank cell culture medium or cultured suspension cells in 
medium. Plates were wrapped to protect from light and incubated at 37 ˚C for 2 
23 
 
hours. The colour change was detected using a FLUOstar Omega Microplate 
reader (BMG LabTech, Oretenberg Germany) set to 490 nm absorbance 
detection mode.  
2.2.3 Drug preparation 
MP, allopurinol and oxypurinol were initially suspended in 0.1 M NaOH at 
concentrations of 50 mM. AZA was initially suspended in DMSO at 100 mM 
febuxostat was dissolved in DMSO at 50 mM. All drugs and reagents were 
purchased from Sigma (Gillingham, UK) except febuxostat was purchased from 
Carbosynth (Compton, Berkshire, UK) and all stock solutions were stored at -80 
⁰ C. Stock solutions of each drug were diluted in relevant medium at 
concentrations shown in Table 2.1. A control vehicle (CV) solution was also 
prepared by diluting NaOH or dimethyl sulfoxide (DMSO) in relevant medium to 
give the same concentration of vehicle as the concentration of vehicle used in 
the medium containing the drug. A serial dilution of 1:2 of medium containing 
the drug and CV was made, producing a range of eight concentrations of drug 
for sensitivity testing. 
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Drug Final Concentration 
(concentration in medium) 
Dilution in Medium 
Before Addition to 
Cells 
AZA 100 μM (200 μM) 1:500 
MP 50 μM (100 μM) 
100 μM (400 μM) 
1:500, 
1:125 
Allopurinol 1 mM (2 mM and 4 mM for dilution with 6-MP) 
100 μM (200 μM and 400 μM) 
10μM (20 μM and 40 μM) 
1:25 and 1:12.5 
1:250 and 1:125 
1:2500 and 1:1250 
Oxypurinol 1 mM (2 mM) 1:25 
Febuxostat 1 mM (2 mM) 1:25 
 
Table 2.1 Dilutions of drugs added to cell plates. 
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2.2.4 Drug Sensitivity Assay 
Cells were plated in rows B-G of columns 3-11 of a 96 well microplate, 100 μL 
of 5 x 105 cells/mL were used. Rows B-G of column 2 was filled with 200 μL of 
medium. All other wells were filled with sterile phosphate buffered saline (PBS), 
pH 7.45, 10 mM phosphate (Gibco life Technologies, Paisley, UK). Plates were 
incubated for 24 hours at 37 ⁰C. 100 μL of CV or drug was then added to each 
cell-filled well and each of the eight serially diluted drug concentrations was 
added to one column of wells (6 wells). In the case of combination studies with 
allopurinol one column of cells had allopurinol at 2 mM, 200 μM or 20 μM, and 
dilution 1:250 0.1M NaOH, to give final concentrations of 1 mM 100 μM and 10 
μM of allopurinol, each in two wells. Serial dilution of MP from a top 
concentration of 100 μM (concentration when added to cells) was added to 
allopurinol at a concentration (on cells) of 1 mM, 100 μM or 10 μM, each 
concentration such that each combination of drugs was in two wells per plate. 
Plates were then incubated for 72 hours, approximately equivalent to 3 
doublings, before being assayed by MTS assay.  
2.2.5 Statistical analysis 
Data were processed using Microsoft Excel and R (Team, 2014). Means of 
percentage survival, compared to the survival of cells grown with only CV, 
means of six wells were determined in Microsoft Excel. 
The data for cell survival in response to XO inhibitors were initially fitted to 
either a linear (1st order) model or a 2nd order polynomial using the lm function 
in R for response against dose. These two models for each data set were 
compared by analysis of variance using the anova function in R. If there was no 
significant difference, at the p-value < 0.05 level, between the two models then 
the simple linear model was used in further analysis; if there was a significant 
difference then the 2nd order polynomial was used. A new model (either linear or 
2nd order polynomial, as appropriate) was then created for each drug in each 
data set including the biological repeats as a variable. The two models were 
then compared using the anova function as above. If there was no significant 
difference, at the p-value < 0.05 level (indicating that the data points within each 
experiment could be considered as independent in the context of all 
experiments when considered together), then the anova function was used to 
derive the significance for the effects of dose using the model of dose versus 
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response alone for the combined data set. Where models which included the 
experimental repeats as a factor were significantly different from the simpler 
model without experiment as a factor, all three biological replicates were used 
analysed separately using t-tests to assess the significance of individual 
parameters. 
For the sensitivity assay with AZA, MP and MP with allopurinol 4-parameter 
logistic curves were fitted to each of the 3 biological replicates and effective 
dose (ED) 50 were determined using the drm function from the drc package in 
R (Ritz and Streibig, 2005). The mean and standard deviation (SD) of these ED 
50 values were determined in R. The difference between AZA and MP was 
determined using a T-test in R to compare the ED 50 values of each drug. In 
order to determine if the various combinations of MP and allopurinol differed in 
their effects from MP alone, analysis of variance using the ANOVA function and 
a Dunnett’s test was used to compare the ED 50 of each of the drug 
combinations to the ED 50 of MP alone, this accounts for multiple tests being 
made using one control. This test was performed by modelling the effects of 
allopurinol dose, as discreet categories not a continuous variable, on the ED 50 
values of each drug combination. This model was assessed by analysis of 
variance using the aov function in R. This model was then subjected to the 
Dunnett’s test using the glht, generalised linear hypothesis test, function from 
the multcomp package in R described in Hothorn et al. (2008). 
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2.3 Results 
2.3.1 Sensitivity of lymphocyte derived cell lines to XO inhibitors 
All three cell lines, MOLT-4, Jurkat MTAP -/- and Jurkat MTAP +/+, were tested 
for their cell survival response to allopurinol (Figure 2.1), its active metabolite 
oxypurinol (Figure 2.2), and febuxostat (Figure 2.3). This was to inform the 
setting up of subsequent experiments when growing cells for metabolite 
measurements to avoid loss of cells due to growth with an XO inhibitor.  
The survival of MOLT-4 cells in the presence of allopurinol was best described 
by a 2nd order polynomial model. Models fitted with and without experimental 
repeats as a factor were not significantly different, and all experimental data 
were analysed together as a simple 2nd order model. This model did not show 
a significant effect of dose (P= 0.1146), indicating that allopurinol had no effect 
on MOLT-4 cell survival. The response of Jurkat MTAP-/- cells to allopurinol 
was best fitted by a linear model; however dose significantly increased survival 
in Jurkat MTAP -/- cells (P=0.0399), although the effect was small and likely to 
be heavily influenced by the data for the highest dose (Fig 2.1b). The survival of 
Jurkat MTAP +/+ cells with allopurinol was also best fitted by a simple linear 
model with no effect of experimental repeat, and  there was no significant effect 
of allopurinol dose on the survival of Jurkat MTAP +/+ cells (P= 0.762). 
The survival of MOLT-4 cells cultured with oxypurinol was best fitted by a linear 
model in which experimental repeat had to be included as a factor. The effect of 
dose was not significant in two out of the three biological repeats, one repeat 
showed a significant increase in cell survival  (P= 0.00239). Therefore, 
oxypurinol had a somewhat variable effect on MOLT-4 cell survival but did not 
significantly reduce cell survival. The response of Jurkat MTAP-/- cells to 
oxypurinol was fitted by a linear model with experimental repeats as a factor, 
but since only one repeat showed a significant reduction in cell survival (P 
=0.000798) the data suggest that oxypurinol does not, overall, have a 
significant effect on cell survival. Conversely, the effect of oxypurinol on Jurkat 
MTAP +/+ cells was linear with no effect of repeat, with a small but significant 
decrease in viability with increased dose (P= 0.000118) (Figure 2.2c). 
The effects of febuxostat on MOLT-4 and Jurkat MTAP -/- cells were best 
described by linear models with experimental repeat as a factor. Febuxostat 
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caused a significantly dose dependent reduction in MOLT-4 and Jurkat MTAP -
/- cell survival (P<0.05) (Figure 2.3b) Jurkat MTAP +/+ cells were also affected 
by febuxostat; in this case a 2nd order polynomial with with no experimental 
repeat as a factor was the best fitting model in which febuxostat dose 
significantly decreased cell viability (P<0.001). 
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a 
b 
c 
Figure 2.1 Cell survival curves showing sensitivity to allopurinol points are means, 
error bars 1 SD and curves are linear or 2nd order polynomial models fitted in R a 
MOLT-4 2nd order polynomial (n=3) b Jurkat MTAP-/- linear model (n=3) c Jurkat 
MTAP +/+ linear model (n=3)  
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a 
 b 
c 
Figure 2.2 Cell survival curves showing sensitivity to oxypurinol curves are linear 
models fitted in R a MOLT-4 points biological replicates, lines models fitted to each 
biological replicate b Jurkat MTAP-/- points biological replicates, lines models fitted to 
each biological replicate c Jurkat MTAP +/+ points are means, error bars 1 SD  
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 a 
 b 
c 
Figure 2.3 Cell survival curves showing sensitivity to febuxostat curves are linear or 2nd 
order polynomial models fitted in R a MOLT-4 points biological replicates, lines models 
fitted to each biological replicate b Jurkat MTAP-/- points biological replicates, lines 
models fitted to each biological replicate c Jurkat MTAP +/+ 2nd order polynomial (n=3) 
points are means, error bars 1 SD  
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2.3.2 Sensitivity of MOLT-4 cells to thiopurine drugs 
MOLT-4 cells have endogenous MTAP activity whereas Jurkat cells lack 
endogenous MTAP activity which affects metabolism and sensitivity to 
thiopurines (Coulthard et al., 2011). Therefore the model was based on data 
collected in MOLT-4 cells. The sensitivity of MOLT-4 cells to MP was tested to 
ensure that the cell line was appropriate to produce data for a model of 
thiopurine metabolism in sensitive cells. AZA caused cell death in a dose 
dependent manner with less than 10% cell survival at a dose of 100 µM AZA 
(Figure 2.4 a). MP caused cell death in MOLT-4 cells at concentrations between 
50 μM and 0.4 μM (Figure 2.4 b). The mean ED 50 for MP was 2.9 μM (SD 
0.78), compared to a mean ED 50 of 6.0 μM (SD 0.44) for AZA from 3 biological 
repeats. In MOLT-4 cells MP was significantly more toxic than AZA (P< 0.01). 
2.3.3 Sensitivity of MOLT-4 cells to a combination of MP and allopurinol 
Combination studies of MP with allopurinol were done on MOLT-4 cells to 
determine how the addition of allopurinol affects the cytotoxicity of MP. When 1 
mM allopurinol was added to MP (10 times the highest dose of MP) there was a 
large reduction in the toxicity of MP. The ED 50 increased more than 10 fold 
from 2.9 μM to 43.0 μM, this was a highly significant (P< 0.001) decrease in 
sensitivity. In contrast 100 μM allopurinol appeared to increase MOLT-4 
sensitivity to MP, the ED 50 dropped to 1.0 μM, this was a non-significant 
increase in sensitivity (P=0.980). With 10 μM allopurinol the ED 50 of 6-MP was 
slightly lowered to 2.1 μM, this difference was not statistically significant (P= 
0.999) (Table 2.2 and Figure 2.5). 
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a 
 
 
b 
Figure 2.4 Cell survival curves showing sensitivity of MOLT-4 cells to thiopurines. 
Points are means, error bars 1 SD and curves 4 parameter logistic curves based on 3 
repeats determined with DRC package in R a AZA b MP. 
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Drug 
MP 
Mean  
(SD) 
n=3 
MP plus 10 µM 
allopurinol 
Mean  
(SD) 
 n=3 
MP plus 100 µM allopurinol 
Mean 
(SD) 
n=3 
MP plus 1 mM 
allopurinol 
Mean  
(SD) 
n=3 
Effective Dose 50 
(ED50) 
2.9e-06 
(7.8e-07) 
2.1e-06 
(1.3e-06) 
1.0e-06 
(7.7e-07) 
4.3e-05 
(1.5e-05) 
P value from 
Dunnett contrasts 
Control not applicable 0.999 0.980 <0.001 
 
Table 2.2 ED50 concentrations of Aza and MP and MP in combination with allopurinol in MOLT-4 cultured cells mean and SD 
(n=3) data processed using DRC in R 
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Figure 2.5 Cell survival curves showing sensitivity of MOLT-4 cells. Points are means 
(n=3), error bars 1 SD and curves 4 parameter logistic curves determined with DRC 
package in R black, MP plus 1 mM allopurinol, red MP with 100 µM allopurinol, green 
MP with 10 µM allopurinol and blue MP alone. 
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2.4Discussion 
MOLT-4 cells show no reduction in cell survival in response to either allopurinol 
or oxypurinol, its active metabolite. The survival of MOLT-4 cells cultured with 
oxypurinol slightly increased in some cases. This is important to note given that 
subsequent work has considered the effect of combining allopurinol with MP on 
cell survival. 
The effect of allopurinol on Jurkat MTAP +/+ cells was not significant and in 
Jurkat MTAP -/- cells allopurinol increased cell survival. Oxypurinol had no 
significant effect over three biological repeats on Jurkat MTAP -/- cell survival, 
although one repeat showed a significant reduction in cell survival with 
oxypurinol. The survival of Jurkat MTAP +/+ cells was reduced. 
A serum concentration of 1.7 mM allopurinol has been shown to cause severe 
side effects and sometimes fatality in patients (Tam and Carroll, 1989). A more 
usual therapeutic allopurinol serum concentration is around 20 µM (Day et al., 
2007) suggesting that 1 mM allopurinol might have off target effects which may 
contribute to the variable cellular response to this concentration of drug. This 
concentration of allopurinol was difficult to dissolve, it is therefore possible that it 
was not fully dissolved and therefore in some repeats not at the correct 
concentration, also contributing to variability. This variability means that only 
very tentative conclusions may be drawn from this data. 
Febuxostat was cytotoxic to all three cell lines; however in no cases was a 
plateau in cell survival reached making it difficult to determine ED 50 values. As 
the maximum concentration of febuxostat used was determined by its solubility 
no extension of the experiment could be made to determine ED50 values. It has 
previously been shown that allopurinol allows TNF related apoptosis-inducing 
ligand induced cell death in TNF-related apoptosis-inducing ligand resistant 
prostate cancer cell lines. This was shown to be due to a XO dependent 
reduction in C/EBP homologous protein levels (Yasuda et al., 2008); C/EBP 
homologous protein is important to DNA damage induced apoptosis. It is 
possible that this or a similar effect due to XO inhibition may be the cause of the 
reduction in cell survival in cells treated with febuxostat. 
Given the purpose of the experiments was to provide preliminary data for model 
building it would have been useful to assess the ED 50 of these drugs with 
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regard to XO inhibition as well as cytotoxicity. This would provide data to help 
fix the magnitude of XO inhibition by a given concentration of allopurinol in the 
computational model. 
As previously reported MOLT-4 cells are sensitive to MP with a previously 
reported ED 50 value of 2.9 μM for MP after 72 hours, a very similar value to 
that observed here 3.21 μM (Fotoohi et al., 2006a). This value is also in the 
reported range of maximum serum concentration in leukaemic patients. Values 
reported range from lower than detectable to around 600 ng/mL and 150 ng/mL 
is equivalent to 1 μM suggesting that these are clinically relevant values (Sulh et 
al., 1986). MOLT-4 cells are slightly but significantly more sensitive to MP than 
to AZA. 
Combining MP and allopurinol significantly reduced the cytotoxicity of MP when 
allopurinol was added at a much higher concentration than MP. When 
allopurinol was added at an equal or lower concentration than MP the sensitivity 
to MP was increased but not significantly. The effect of combining allopurinol 
and MP has not been previously studied in lymphocyte cell lines so no 
comparison can be made to previous data. The causes of these changes in the 
sensitivity to MP will begin to be examined later in this study, initially by 
examining the metabolite levels in cells treated with a combination of allopurinol 
and MP and also by testing possible mechanisms for these changes using a 
computational model of thiopurine metabolism.  
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2.5Conclusion 
MOLT-4 cells are sensitive to MP and therefore a suitable model for the 
collection of parameters of MP metabolism to inform a computational model of 
MP metabolism. 
The sensitivity of the MOLT-4 cells was different when MP was combined with 
allopurinol thus indicating that this system would also be suitable for exploring 
the effect of combing these two drugs using computational modelling. 
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Chapter 3.  Development of a method for detecting thiopurine 
metabolites 
3.1 Introduction 
To develop a dynamic computational model of a biochemical system such as 
thiopurine metabolism, quantitative data are necessary to calibrate and validate 
the model. For this project some rate constants were derived from the literature 
however, not all of the kinetic parameters have been previously described. To 
estimate the remaining parameters, quantitative data about the changing 
concentration of as many as possible of the species being modelled need to be 
collected. Such data will allow estimates to be made of the kinetic parameters 
needed to produce these changes using software designed for this kind of 
estimation (for more details see Chapter 5). Simultaneous measurements need 
to be made of the concentrations of various thiopurine metabolites in cultured 
cells grown with MP. To this end a sensitive and reliable method capable of 
measuring a range of thiopurine metabolites is required. 
A variety of methods for the detection of thiopurine metabolites have been 
developed, initially for use in a laboratory setting but later  to permit analysis in 
a variety of cell types and body fluids. The first methods relied on paper 
chromatography (Maddocks and Davidson, 1975) but this has long been 
superseded by high pressure liquid chromatography (HPLC) (Breter, 1977) and 
increasingly by liquid chromatography mass spectrometry (LC-MS/MS) 
(Hofmann et al., 2012; De Nicolo et al., 2014). Methods for measuring 
thiopurine metabolites in a range of cellular compartments have been 
described: RBCs (Dooley and Maddocks, 1982; Lennard and Maddocks, 1983; 
Erdmann et al., 1990; Lennard and Singleton, 1992; Weller et al., 1995; 
Dervieux and Boulieu, 1998a), lymphoblasts (Dervieux et al., 2002), isolated 
lymphocytes (Erdmann et al., 1991), leukocyte DNA (Warren et al., 1995; 
Cuffari et al., 1996a; Wang and Wang, 2010b; Jacobsen et al., 2012), plasma 
(Dooley and Maddocks, 1980; Andrews et al., 1982; Lin et al., 1991; Su et al., 
1999), whole blood (Pike et al., 2001; Kirchherr et al., 2013; Vikingsson et al., 
2013) and urine (Weller et al., 1995). The most recent method uses LC-MS to 
detect TG and me MPR in isolated lymphocytes (De Nicolo et al., 2014). HPLC 
has also been used to analyse the kinetics of MP metabolism in the lysate of 
cultured cells (Kalra et al., 2007), a similar task to collecting data to estimate the 
40 
 
parameters of a dynamic model, suggesting that this may be an appropriate 
method to collect the data necessary for model parameter estimation. 
3.1.2 Liquid chromatography and mass spectrometry  
Previous methods of detecting thiopurine metabolites (Erdmann et al., 1990; 
Lennard and Singleton, 1992; Dervieux and Boulieu, 1998a) have mostly used 
reverse phase HPLC. This is a method of separating chemicals by the relative 
affinities with which they bind a non-polar stationary phase (column packing) 
and the ability of a polar buffer to remove that affinity. Analytes are then 
detected by another means which in the case of thiopurine metabolites has 
commonly been by either UV absorbance (Lennard and Singleton, 1992; 
Dervieux and Boulieu, 1998a) or detection of fluorescence (Pike et al., 2001; 
Vikingsson et al., 2013). However more recent methods have used mass 
spectrometry (MS) to detect metabolites (Hofmann et al., 2012; De Nicolo et al., 
2014).  
Ion-exchange chromatography separates analytes based on ionic interactions 
between polar analytes and an oppositely charged polar stationary phase. It is 
commonly used for separation of oligonucleotides and therefore may be 
suitable for detecting thiopurine nucleotides. HPLC can be coupled to MS to 
detect analytes with a greater sensitivity than UV absorbance or fluorescence 
methods. MS detects metabolites based on their mass to charge ratio after 
ionisation and in the case of tandem MS on their fragmentation pattern when a 
charge is applied. A sample is ionised, in the case of electospray ionisation 
(ESI), by passage through a charged probe which passes a charge to the 
sample as it passes through. This is then vaporised and enters a first 
quadrupole where an initial separation by mass to charge ratio is made. These 
ions then enter a second quadrupole where they are fragmented by 
bombardment with argon or nitrogen gas in a vacuum, and form 
characteristically sized fragments. This allows further separation of the analyte 
mixture with the same initial mass to charge ratio, using the mass to charge 
ratio of these fragments in the third quadropole. The fragment of interest can 
then be quantified using a photo-multiplier based detection system. Recent 
advances in MS technology have led to the development of assays for 
thiopurine metabolites using this method. De Nicolo et al. have used the 
increased sensitivity to apply the assay to isolated lymphocytes (a less 
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abundant cell type than RBCs) (De Nicolo et al., 2014), whilst Hoffman et al has 
used the ability of MS to uniquely identify many similar compounds to produce 
an assay capable of simultaneously measuring 11 thiopurine metabolites 
(Hofmann et al., 2012). Both of these characteristics of LC-MS/MS make it an 
attractive method to develop to measure metabolites both to inform 
development of a computational model and as a novel clinical assay. 
3.1.3 Measurement of thiopurine metabolites in clinical use 
There have been several analyses of the effectiveness of thiopurine metabolite 
measurements at predicting the outcome of thiopurine therapy, some 
concluding that metabolite measurements are useful (Osterman et al., 2006; 
Ooi et al., 2007; Moreau et al., 2014) but others do not (Konidari et al., 2014). A 
positive correlation between TGNs in RBCs and the likelihood of a good 
outcome of treatment (Schmiegelow et al., 1995; Dubinsky et al., 2000; Cuffari 
et al., 2001; Wright et al., 2004; Ooi et al., 2007) has been shown several times 
in both leukaemia and IBD. Also me MPR in RBCs, used as representative of 
methylated inosinic metabolites, has been shown to correlate positively with the 
likelihood of hepatotoxicity (Dubinsky et al., 2000; Dubinsky et al., 2002; Derijks 
et al., 2004).  The ratio between methylated metabolites and TGNs is used by 
some gastroenterologists to determine which patients should be treated with a 
combination of AZA and allopurinol. A high methylated to TGN ratio indicates 
that the patient may benefit from AZA and allopurinol combination and a 
reduction in this ratio is seen a sign that this treatment is likely to be successful 
(Sparrow et al., 2005; Leung et al., 2009). 
Some of the lack of consistency in the assessments of the utility of thiopurine 
metabolite measurements to predict efficacy may be due to method-dependent 
variation in thiopurine metabolite levels as described in Chapter 1. It should also 
be noted that RBCs are not the target cells for thiopurine drugs but are chosen 
as the cell type for assessment of TGN levels largely due to their abundance. 
Thiopurines target immune cells and leukaemic blasts depending on the 
condition being treated. These target cell types are nucleated cells and 
therefore have IMPDH and are able to metabolise thiopurines, as described in 
Chapter 1. Mature RBCs are anuclear, lack IMPDH and therefore are not able 
to produce TGMP but rely on transport from their extra-celluar environment. 
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Measurements of TGNs in RBCs only indirectly reflect their production and 
levels in target cells and therefore their efficacy. 
Despite these issues, several studies of the correlation between reported 
metabolite levels and outcome show that TGN measurement correlates with 
remission in IBD and leukaemia, indicating that metabolite measurement is a 
useful clinical tool (Schmiegelow et al., 1995; Osterman et al., 2006; Ooi et al., 
2007; Nguyen et al., 2013). A more direct measurement of thiopurine 
metabolites in more-clinically-relevant cell types may prove a more sensitive 
indicator of clinical efficacy and would also be a useful research tool for 
improving understanding of the mechanisms of thiopurine action. 
The aim of this part of the project was to develop an assay that would be able to 
detect as many thiopurine metabolites as possible accurately and with sufficient 
sensitivity to detect them in cell cultured cells. A subsidiary aim is to make the 
assay suitable for detecting a range of thiopurine metabolites in patient 
samples. 
3.1.4 Aims 
1. To develop a method to detect a range of thiopurine metabolites in cell 
culture cells using either HPLC or LC-MS/MS. 
2. To show the sensitivity and reliability of such a method. 
3. To show the applicability of such a method to cultured cells and patient 
blood samples 
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3.2 Methods  
3.2.1 Preparation of standards for LC-MS/MS 
TGMP, TGDP, TGTP, meTGMP, meTGDP, meTGTP, meTIMP, meTIDP, 
meTITP and TIMP were purchased from Jena Biosciences (Jena, Germany) as 
10 mM solutions. MP, XMP and allopurinol were bought from Sigma (Sigma, 
Gillingham, UK) in powder form. Analytes purchased as powder were dissolved 
in 0.1 M NaOH to 50 mM. Dilutions of all analytes were then made in MilliQ 
filtered, deionised water. 
For analysis of patient samples, a mixture of TGMP, TGDP,TGTP, meTGMP, 
meTGDP, meTGTP, meTIMP, meTIDP, meTITP and TIMP standards was 
used; a 100 μM stock solution of this mixture was made and stored at -20 °C. A 
standard curve was prepared by dilution of stock solution in water to 50 nM then 
eight serial dilutions from 50 nM to 0.159 nM. Quality controls (QCs) were 
prepared by the same method at concentrations of 30, 15 and 3 nM. 
During method development and for analysis of initial cell culture samples, the 
mixture used for the standard curve also included MP, and allopurinol. 
Standards from 31.25 nM to 0.488 nM were prepared by serial dilution in water; 
QCs were also made by dilution in water to 62.5, 31.25, and 15.25 nM and in 
some cases 250 nM. 
3.2.2 Preparation of patient samples for LC-MS/MS 
Blood from patients receiving a variety of thiopurine drugs was sent to 
Newcastle in Ethylenediaminetetraacetic acid (EDTA) tubes. Within 24 hours of 
sampling, 4 mL of blood was diluted 1:1 with PBS then layered onto 8 mL 
LymphoprepTM under sterile conditions. This was then centrifuged for 30 min at 
800 g without braking. The mononuclear cell layer, containing peripheral blood 
mononucleocytes (PBMCs), was removed and remaining RBC were lysed by 
mixing with 20 times the volume of RBC lysis buffer (0.15 M ammonium 
chloride; 0.01 mM potassium bicarbonate and 0.1 mM EDTA). After 10 minutes 
the mixture was centrifuged to obtain a cell pellet which was washed twice with 
PBS and stored at -80 ⁰C. The washed cell pellet was resuspended in 200 μL 
water and sonicated on ice 3 times for 5 seconds each at amplitude 5. They 
were then centrifuged for 5 min in a microcentrifuge at 16,873 x g and the 
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supernatant transferred to a glass insert for analysis with 10 μL retained for 
protein measurement by Pierce bicinchoninic acid (BCA) assay. 
From the RBC layer present after Lymphoprep centrifugation and mononuclear 
cell removal, three aliquots of 200 µL each of RBCs were removed and washed 
twice with 1 mL of PBS before being frozen at -80 ⁰C. When defrosted, the 
RBCs were diluted 1:100 in MilliQ water then sonicated at amplitude of  5 for 10 
s, centrifuged 16,873 x g  for 5 minutes and the supernatant transferred to a 
glass insert for analysis with 5 μL retained for protein quantification by Bradford 
assay. The Bradford assay was used with RBC samples due to its suitability for 
use with samples containing haemoglobin, whereas the Pierce BCA assay is 
not suitable for these samples. 
(Some samples were prepared by Dr. Sally Coulthard.) 
3.2.3 Preparation of cultured cells for analysis by LC-MS/MS 
Cells were grown as described in Chapter 2 and 5. Cell pellets of approximately 
3 x 106 cells were stored at -80  ͦC prior to analysis. 
Cell samples were defrosted and resuspended in 200 μL of MilliQ filtered water. 
They were then sonicated on ice for 10 seconds at amplitude 4, centrifuged for 
7 min in a microcentrifuge at 3000 g and the supernatant transferred to a glass 
insert for analysis; a 10 μL aliquot was retained for protein measurement by 
Pierce BCA assay. 
3.2.4 Protein quantification by Pierce bicinchoninic acid and Bradford 
assays 
The total protein in PBMCs and cell culture samples was measured using a 
Pierce BCA protein assay which is based on the Biuret reaction (reduction of 
Cu2+ to Cu1+ by protein) followed by chelation of BCA by the Cu1+ ions to 
produce a purple colour detectable colourimetrically at 562nm. The BCA 
reaction amplifies the signal so that a lower detection limit is possible than with 
a Biuret reaction alone.  
The assay was performed in a 96-well plate. A standard curve made with 
2mg/mL bovine serum albumin (Thermo Fischer) diluted to 0.2, 0.4, 0.6, 0.8, 1.0 
and 1.2 mg/mL in deionised, filtered water was placed in four wells per standard 
and eight wells contain distilled water as a blank. 10 μL of standard, blank or 
appropriately-diluted cell lysate sample was added to each well and then 190 μL 
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of reaction solution made following the manufacturer’s instructions was added. 
Incubation was for 30 min at 37 ͦ C. The plate was then read using a FLUOstar 
Omega Microplate reader (LabTech, Oretenberg Germany) at 562 nm. 
Another assay which is more accurate for protein quantification in samples 
which include haemoglobin, the Bradford assay, was used to analyse the RBC 
lysate. The Bradford assay relies on the covalent bonding of hydrophobic parts 
of proteins to Coomassie Blue dye to produce a solution with an absorbance at 
595 nm. 
The assay was performed in a 96-well plate. A standard curve of 0.05, 0.1, 0.2, 
0.4 and 0.6 mg/mL of bovine serum album (Thermo Fischer, Loughbourgh, UK) 
diluted in deionised, filtered water was prepared. 10 μL of standard, deionised, 
filtered water (blank) or diluted cell lysate was added to each well. 200 μL of 
Bradford reagent (BioRad, Hemel Hempsted, UK) diluted 1 in 5 was added to 
each well and incubated for 30 min at room temperature. The plate was read at 
595 nm using a FLUOstar Omega Microplate reader (LabTech, Oretenberg 
Germany). 
3.2.5 Liquid chromatography tandem mass spectrometry  
This method was developed with help from Mr Philip Berry, particularly during 
the tuning stages and early development of the chromatography method. Some 
further development of the chromatography method and all runs collecting data 
for this project were carried out independently.  
LC-MS/MS was carried out on a Shimadzu Prominence UFLC (Shimadzu, 
Kyoto, Japan) for chromatographic separation combined with an API4000 triple 
quadrupole LC-MS/MS (Applied Biosystems, California, USA) for tandem mass 
spectrometry (MS/MS) analysis. 
A Clarity Oligo-WAX column (150mm x 4.6mm) and SecurityGuard Oligo-WAX 
column (4 x 3mm) both from Phenomenex (Cheshire, UK) maintained at 30◦C 
were used with two ammonium acetate mobile phases of pH 8 (Buffer A) and 
pH 10.01 (Buffer B) for chromatographic separation of analytes. Mobile phases 
were prepared by weighing 1.5 g glacial acetic acid (ThermoFischer Scientific) 
and adding water. The pH was adjusted to pH to 8 or 10.01 with ammonia 
(ThermoFischer Scientific) and the final weight was adjusted to 500 g. The 
gradient system had a starting condition of 90% Buffer A followed by a 0.5 
46 
 
minute gradient to 80% Buffer A at 1.5 minutes. This was followed by a 2 
minute gradient from 80% Buffer A to 100% Buffer B at 3.5 minutes with those 
conditions maintained until 13.5 minutes when the column was returned to 10% 
Buffer A in a 0.5 minute gradient. The flow rate was 0.7 ml/minute and a post-
column flow splitter was utilised to divert 70% of mobile phase to waste to 
improve ionisation. 
LC-MS/MS analysis with electrospray ionisation was performed in positive 
ionisation mode using nitrogen gas at the following optimised settings: curtain 
gas, 10; ion source gas 1, 40; ion source gas 2, 50; ion spray voltage, 5500; 
collision gas, 6; entrance potential, ionisation temperature, 400˚C. (Optimisation 
was performed by Mr Philip Berry and Dr Sally Coulthard for several analytes 
and by me with the help of Mr Philip Berry for the rest.) Optimisation of MS/MS 
parameters for all analytes was performed by selecting precursor ions and 
determining the four most prominent product ions. The three best of these were 
then further optimised for fragmentation and voltage parameters. Quantification 
of analytes was performed in multiple reaction monitoring (MRM) mode mass 
transitions and optimised MS/MS parameters are given in Table 3.1. Analyst® 
software v1.5 (AB SCIEX, Framingham, USA) was used for sample analysis, 
peak integration and analyte quantification.  
  
47 
 
  
 
Table 3.1 Chromatographic and mass spectrometry detection characteristics of 
analytes. 
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3.2.6 Determination of variability 
In order to determine the intra-day variability of the assay five injections of three 
QCs, one each at 3 nM, 15 nM and 30 nM, were made. The co efficient of 
variation of these five injections was determined (Mean/SD). This was repeated 
on five separate days in order to determine the inter-day variability. 
3.2.7 Determination of matrix effect 
Matrix effect was determined by adding 200 µL of 3 nM, 15 nM and 30 nM QC 
to either pelleted PBMCs or RBCs obtained from healthy, untreated volunteers. 
The sample was then sonicated and centrifuged as described for patient and 
cell culture samples. The concentration of each analyte calculated from these 
samples was then compared to injections of the same QCs without cell lysate. 
  
49 
 
3.3 Results 
3.3.1 Separation of purine nucleotides and analogues by LC-MS/MS  
TIMP and XMP both have a molecular mass of 364 g/mol, ionic mass of 365.07 
and produce a fragment to give the same Q3 mass, 153.1. The equipment was 
tuned to detect TIMP but when control cells (not grown with thiopurine drug) 
were assayed, a peak was evident in the TIMP mass channel at approximately 
the expected retention time for TIMP. This was due to XMP giving the same 
fragmentation pattern as TIMP, confirmed with XMP standard; however, it was 
possible to separate the two peaks by adjusting chromatography conditions 
whilst preserving the distinct peaks of the other metabolites. As shown in Figure 
3.1 TIMP and XMP are distinguishable chromatographically but not by 
molecular mass or fragmentation pattern. 
 
Also extra peaks were visible in the chromatograms for TGMP, TGDP and 
TGTP standards (Figure 3.2 a), these correspond to the retention times for 
meTIMP, meTIDP and meTITP. The mass of TGMP, TGDP and TGTP differ 
from meTIMP, meTIDP and meTITP respectively by only 1 the resolution of the 
mass spectrometer is 2, therefore it is likely that these extra peaks are meTIMP, 
meTIDP and meTITP. 
  
50 
 
a 
b 
c 
Figure 3.1 Chromatograms from Analyst a TIMP injected alone with 8.91 minutes 
retention time of XMP b XMP injected alone 8.61minutes retention time and c TIMP 
and XMP injected together.  
51 
 
3.3.2 Variability of standards analysed by LC-MS 
Intra-day and inter-day variability was assessed for a total of 16 analytes; 
endogenous purines (adenosine triphosphate (ATP), GTP and XMP), a XO 
inhibitor (allopurinol, which is also a purine analogue) and thiopurine 
metabolites (AZA, MP, meTGTP, meTGDP, meTGMP, TGTP, TGDP, TGMP, 
meTITP, meTIDP, meTIMP, TG and TIMP). This assessment originally took 
place between October and November 2013.  However the results of these runs 
were inadequate and as briefly discussed below, these experiments were re-run 
using a revised protocol in May and June 2014. These results are discussed in 
more detail. 
Food and Drug Administration (FDA) guidelines for bioanalytical method 
validation (Administration, 2001) propose an inter-day covariance of less than 
15% for the QCs and less than 20% for the lowest QC is acceptable for clinical 
assays. On initial analysis in 2013, metabolites showed an inter-day variability 
of less than 15% at all QC levels (31.25 nM, 62.5 nm, 125 nM and 250 nM). 
However allopurinol and meTITP had higher variability at 31.25 nM QC of 28% 
and 18% respectively. The preferred upper limit of variability for an assay is 
20% for the lowest QC so the lowest safe QC for allopurinol was 62.5 nM. 
In 2013 coefficients of variance between days were frequently unacceptably 
high. This was particularly the case for allopurinol at the lowest QC 
concentration. Other metabolites also showed considerable variation between 
repeated injections of at least one QC on several days. However on many 
occasions the intra-day variability was well below the required level. 
Most differences from expected value of QCs for each day were in the range of 
10% to 15% however there were many examples which show a smaller 
difference from expected values in 2013. All analytes differed from the expected 
QC value by 2% or less from the expected values at least once. Despite this, 
many QCs showed differences from control of between 20% and 30% 
difference from control. This was unacceptably high. The most extreme 
example was meTITP which at 31.25 nM showed a difference from control of 
36% with a calculated value of 20 nM.  
Due to this high variability between runs the protocol was revised, buffer pH 
was controlled more precisely by taking account of temperature variation, inter-
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day and intra-day assay variability was re-determined. The limit of detection 
(three times the baseline) for the majority of metabolites was 0.391 nM whilst 
meTGDP and TIMP were detectable to 0.195 nM (Table 3.6). The lower limit of 
quantification is the lowest level at which a value can be assigned to a sample. 
According to FDA guidelines (FDA, 2001) this should be 5 times the baseline, 
however as for some analytes this was below the lowest sample used or at a 
level where samples showed high variability the lowest used concentration 
which showed less than 15% variability was used. The lower limit of 
quantification was 0.391 nM for most metabolites. For meTGMP, meTIMP, 
meTIDP and TIMP the lower limit of quantification was 0.781 nM. These values 
were adequate for the detection of thiopurine metabolites in patient samples as 
(Table 3.4) The upper limit of the linear range described is the maximum 
standard injected, 50 nM; this also appears adequate for quantifying 
metabolites in patient samples (Table 3.4). However, a higher standard curve 
was used for analysing cell culture samples (Table 3.4 and Figure 3.2b), and 
the reliability of the assay was acceptable to 250 nM in the earlier analysis. QCs 
up to 1000 nM were injected where necessary and these showed less than 20% 
difference from expected values on back calculation. The correlation coefficient 
was over 99% for all of the reanalysed analytes except TIMP, showing that the 
quantification of samples will be accurate in the range described. 
As shown in Table 3.2, the intra-day variability was below 5% for the 30 and 15 
nM QCs for all analytes except TIMP and below 10% at the 3 nM QC for all but 
TIMP. The interday variability was below 10% for all analytes except TIMP and 
below 15% for all analytes except TIMP. These low values for variability 
measures show the assay to be repeatable and, therefore, appropriate to 
analyse samples for future research. Nevertheless, the higher variability for 
TIMP show that data collected for TIMP in the 0.781 nM to 50 nM range should 
be viewed with caution and have not been included in the analysis of patient 
samples. TIMP was present at high concentrations in cell culture samples, and 
since the earlier assays had acceptable intra and interday variability at higher 
TIMP concentrations (250 nM to 31.25 nM), data from TIMP have been included 
in the analysis of samples from cell culture. 
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 Analyte 
 
meTGM
P 
meTGDP meTGTP meTIMP meTIDP meTITP TGMP TGDP TGTP TIMP 
LODa 
(pmol/ml) 
0.391 0.195 0.391 0.391 0.391 0.391 0.391 0.391 0.391 0.195 
LLOQb 
(pmol/ml) 
0.781 0.391 0.391 0.781 0.781 0.391 0.391 0.391 0.391 0.781 
Linear 
Range 
(pmol/ml) 
0.781–50 0.391–50 0.391–50 0.781–50 0.781–50 0.391–50 
0.391–
50 
0.391–
50 
0.391–
50 
0.781-
50 
Slopec 3216.98 2034.70 1340.44 1645.89 1722.30 1170.52 
2107.9
3 
1942.6
2 
2392.7
1 
1694.5
4 
Interceptc 237.43 -10.48 -21.70 241.88 10.01 -91.04 -109.03 -533.24 -501.83 -1695.1 
Correlation 
Co-
efficient 
(r2) 
0.9998 0.9998 0.9997 0.9996 0.9996 0.9996 0.9996 0.9997 0.9995 0.9831 
Intra-day 
High QCd 
2.1 1.9 2.1 2.0 1.8 2.2 2.3 1.6 1.7 1.8 
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(%RSD) 
Intra-day 
Medium 
QCd 
(%RSD) 
3.1 2.5 4.5 3.4 2.3 3.6 3.5 2.4 1.9 2.3 
Intra-day 
Low QCd 
(%RSD) 
6.0 6.2 7.1 8.3 5.1 5.7 5.7 5.2 2.8 5.1 
Inter-day 
High QCe 
(%RSD) 
4.9 4.6 5.6 3.8 4.0 6.3 6.1 3.0 5.1 7.8 
Inter-day 
Medium 
QCe 
(%RSD) 
5.3 5.6 4.7 5.9 4.0 4.8 7.1 4.3 7.1 12.5 
Inter-day 
Low QCe 
(%RSD) 
8.5 8.0 4.8 7.6 7.2 7.7 11.6 14 6.2 20.7 
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Table 3.2 (previous 2 pages) Showing the within and between day variability 
of meTGMP, meTGDP,meTGTP, meTIMP, meTIDP, meTITP, TGMP,TGDP, 
TGTP and TIMP as assayed in January and May 2014  
a Limit of detection (S/N = 3; n = 5); b Lower Limit of Quantification (S/N = 5 + 
replicate CV<15%; n = 5); c Calibration curves (y=ax+b); d Intra-day, n = 10; e 
Inter-day, n =5 
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3.3.3 Matrix effect 
The effect of cell lysate on the detection of the nine key metabolites for the 
assay of patient samples was generally quite a large suppression (Table 3.3). 
However levels of a few metabolites showed amplification in cell lysate 
compared to water. Part of the difference in signal may be down to conversion 
between different phosphate forms of the nucleotides, particularly di and tri 
phosphates as previously described (Vikingsson et al., 2013). 
In PBMC lysate meTGTP showed almost complete loss of signal, meTGDP also 
showed a large loss of signal in PBMC lysate and meTGMP showed a gain of 
signal in PBMC lysate. This was different from the situation in RBC lysate in 
which meTGTP showed a large signal gain, meTGDP behaved similarly to in 
PBMC lysate and meTGMP lost some signal in RBC lysate. Overall the 
meTGNs lost around 40% signal in PBMCs lysate but only around 10% in RBC 
lysate. 
In PBMC lysate all methylated thioinosine metabolites showed signal 
suppression, this was greatest for meTITP and least in meTIMP with the sum 
being suppressed by approximately 60%. In RBC lysate meTITP signal was 
amplified by around 50% while meTIDP and meTIMP signals were both 
suppressed. This leads to an overall suppression of around 10% signal. 
Almost all TGTP signal was lost in PBMC lysate but was amplified by around 
50% in RBC lysate. TGDP signal was lost in both PBMC lysate and RBC lysate. 
TGMP signal was amplified in both RBC and PBMC lysate. Overall signal loss 
of TGNs was seen in PBMC lysate. Whereas in RBCs signal loss for TGNs was 
seen at the middle concentration assessed but signal gain was seen at low 
concentration and no effect at high concentration. This is probably due to the 
matrix effect in RBCs being small compared to the variability of TGNs, possibly 
due to oxidation in cell lysate. 
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Analyte Matrix Effect PBMC Matrix Effect RBC 
 
3 nM 15 nM 30 nM 3 nM 15 nM 30 nM 
MeTGTP -101% -101% -100% 125% 77% 48% 
MeTGDP -79% -80% -82% -72% -73% -52% 
MeTGMP 6% 78% 71% -40% -10% -11% 
Sum MeTGN -50% -35% -39% -9% -1% -5% 
MeTITP -67% -91% -95% 58% 53% 17% 
MeTIDP -30% -57% -63% -51% -66% -47% 
MeTIMP -8% -21% -24% -32% -11% -16% 
Sum MeTIN -34% -56% -60% -10% -10% -16% 
TGTP -90% -100% -100% 78% 44% 28% 
TGDP -61% -94% -95% -39% -70% -39% 
TGMP 137% 85% 52% 28% 1% 11% 
Sum TGN -3% -43% -48% 24% -9% 0% 
 
Table 3.3 Matrix effect of PBMC and RBC cell lysate on nine key metabolites 
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3.3.4 Analysis of patient and cultured cell samples 
As shown in Table 3.4 and Figure 3.2 b and c, meTGMP, meTGDP, meTGTP, 
meTIMP, meTIDP, meTITP, TGMP, TGDP and TGTP were detected in samples 
from patients taking thiopurine drugs. They were detectable and quantifiable in 
both RBCs and PBMCs. There was a wide range of levels of most metabolites 
detected in cells from different patients; however, meTIDP, meTITP and TGTP 
were not detectable in any PBMC samples. 
All analytes were detectable in MOLT-4 cells (Table 3.4 and Figure 3.2 a) 
cultured with 10 µM MP for 24 hours. They were found at higher concentrations 
than those seen in patient samples. meTIMP and meTDP and TGMP are 
around 1000 times higher than those detected in patient samples. Further 
discussion of the levels of MP metabolites detected in cultured cells is made in 
Chapter 5. 
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Metabolite 
Range PBMCs 
pmoles/mg 
protein 
Range RBCs 
pmoles/mg 
protein 
Range in MOLT-4 
cells pmoles/mg 
protein 
MeTGMP 0.000-0.693 0.000-0.366 1.854-12.410 
MeTGDP 0.000-0.159 0.000-0.863 1.318-9.643 
MeTGTP 0.000-0.130 0.000-1.396 0.692-3.912 
MeTIMP 0.000-0.569 0.000-2.240 1620.723-3381.285 
MeTIDP 0 0.000-15.428 58.582-194.703 
MeTITP 0 0.000-6.390 2.264-14.433 
TGMP 0.228-1.909 0.000-1.138 164.767-814.253 
TGDP 0.000-0.725 0.000-2.477 8.234-63.507 
TGTP 0 0.000-3.615 1.100-32.856 
 
Table 3.4 The concentrations of various analytes detected in PBMCs and RBCs 
from10 samples from 10 patients on low dose azathioprine plus allopurinol and 
from cells 6 samples of MOLT-4 cells grown with 10 µM MP for 24 hours 
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a 
61 
 
b 
62 
 
c 
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d 
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Figure 3.2 (Previous 4 pages) Chromatograms from Analyst: top panel TGMP 
approximately 8.4 minutes (blue), TGDP approximately 9.0 minutes (red) and 
TGTP approximately 9.5 minutes (green); middle panel, meTIMP approximately 
6.2 minutes (blue), meTIDP approximately 8.2 minutes (red) and meTITP 
approximately 8.8 minutes (green); lower panel meTGMP approximately 7.6 
minutes (blue), meTGDP approximately 8.8 minutes (red) and meTGTP 
approximately 9.2 minutes (green) a 50 nM Standards in water b MOLT-4 cells 
treated with 10 µM MP for 24 hours c PBMCs from a patient treated with low 
dose AZA and allopurinol, d RBCs from the same patient. 
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3.4 Discussion 
Previously available assays for thiopurines were not able to detect a sufficient 
range of metabolites to collect the data needed to estimate the parameters for 
the computational model as they generally only measured TGNs and meMP 
(Lennard, 1987; Dervieux and Boulieu, 1998c; De Nicolo et al., 2014). Hoffman 
published a more suitable method capable of detecting 11 metabolites 
(Hofmann et al., 2012) but only after this project was well under way. Most of 
these previous methods used HPLC to detect TGNS and methylated 
metabolites. However due to the processing steps involved in these methods 
they are unable to distinguish between TGMP, TGDP and TGTP or between 
different methyl thioinosine metabolites and are unable to detect the methyl TG 
metabolites and TIMP, all of which would ideally be measured to provide data to 
inform the computational model. These previous methods are also of insufficient 
sensitivity as they were generally developed to detect metabolites in RBCs, an 
abundant cell type thus facilitating access to lysates with high concentrations of 
metabolites. 
An initial HPLC assay was developed as part of this project which was able to 
assay more metabolites than most previously published methods and reduced 
the pre-analytical processing. However it was insufficiently sensitive and reliable 
to detect all the thiopurine metabolites in cell culture samples or to be used as a 
clinical assay.  
For the LC-MS/MS assay developed during this project to detect analytes, the 
only processing of samples was cell lysis, in the case of cell culture cells, and 
cell separation and lysis in the case of patient samples. There have been 
several recently-developed methods for assaying thiopurine metabolites using 
LC-MS/MS (Hofmann et al., 2012; De Nicolo et al., 2014). Our LC-MS/MS 
assay was between 100 and 1000 times more sensitive than our earlier HPLC 
assay. The method recently developed by Hoffman (Hofmann et al., 2012) was 
able to detect a range of thiopurine metabolites however it was only optimised 
for use with RBC samples and pre-processed with EDTA and DTT. More 
recently a method optimised for use with lymphocyte samples and with a similar 
sensitivity to the method described here was developed (De Nicolo et al., 2014). 
However this method only detects thioguanosine and me MPR. This relies on 
processing of samples by phosphatase which reduces the number of 
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individually identifiable metabolites. This low number of metabolites detected 
makes it unsuitable for use in collecting data to inform a computational model. 
Whereas the method developed for this project was sufficiently sensitive to be 
used to detect metabolites in lymphocytes from patients as well as able to 
detect a wide range of analytes making it suitable for data collection for model 
calibration. 
Other recently developed assays have found, similarly to this assay, that cell 
lysate causes suppression of some analytes and amplification of others 
(Hofmann et al., 2012; De Nicolo et al., 2014). 
As the various phosphate forms of the metabolites have been shown to be 
considerably variable in cell samples (Vikingsson et al., 2013) it was decided 
later in this project that for the purposes of using data, collected using this LC-
MS/MS method, for computational model building the mono, di and triphosphate 
forms of each metabolite group were treated as one species in the model. 
It was also decided that the quality of data collected about ATP and GTP was 
insufficiently reliable to be used to produce a model including these 
endogenous purines. 
It should be noted that metabolite levels in RBCs, PBMCs and cultured cells 
differ. This may suggest that the modelling of MP metabolism in cultured cells 
may not be relied on to describe the situation in patients. These differences may 
also reflect the fact that the cultured cells were treated with MP and the patients 
who provided samples for analysis were treated with a combination of AZA and 
allopurinol. However the magnitude of the difference between cultured cells and 
patient samples is large especially for TGMP and therefore seems likely to 
reflect other differences such as a lack of first pass metabolism by the liver in 
cultured cells. Given that it is difficult to study drug metabolite levels in detail in 
patients this is a difference which must be acknowledged but does not stop the 
use of data collected in cultured cells. 
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3.5 Conclusions 
A method of detecting 9 thiopurine metabolites in patient samples and 16 
thiopurine metabolites or endogenous purines in cell culture samples with 
slightly less reproducibility at low concentrations has been successfully 
developed. This method has begun to be used to investigate the difference 
between RBC and lymphocyte metabolite levels in patients. This shows promise 
for further investigation which may help to optimise clinical metabolite 
monitoring in the future. This method has also been used to produce 
measurements of metabolites in cell culture samples to inform a computational 
model (results described in Chapter 5). 
In the future this method may be used for both further investigation of the 
mechanism of action of thiopurines in vivo and in vitro. Also after a study of 
correlation with clinical outcome it may be able to be used in routine treatment 
monitoring. 
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Chapter 4. Towards an integrated model of purine and 
thiopurine metabolism 
4.1 Introduction 
It was argued in the introduction to this thesis (Chapter 1) that an understanding 
of the complexities of thiopurine metabolism is best addressed using a systems 
level approach rather than focusing in detail on individual components. Previous 
attempts at computational modelling the mechanisms and effects of thiopurine 
metabolism have provided some insight.  
Panetta et al (Panetta et al., 2006) have built a mechanistic model of the effects 
of TGN incorporation into DNA on the cell cycle and fitted data from various cell 
lines with differing sensitivities to thiopurine drugs. The model produced 
suggested that thiopurine resistance developed due to the cells failing to enter 
apoptosis but with a reduced cycling rate. This was confirmed with gene 
expression data showing altered expression levels of genes involved in cell 
cycle and apoptosis control.  
Fransson et al (Fransson et al., 2006; Fransson et al., 2007) used a 
mechanistic model of thiopurine metabolism to model the action of AZA at the 
whole body level in patients over a period of several months. However they had 
limited success in matching their models to the available data. Both of these 
studies indicate that a simpler system informed by more targeted data might 
present a more tractable solution. 
An obvious first step in producing a computational model of thiopurine 
metabolism is to build on a pre-existing well characterized model of 
endogenous purine metabolism, a closely related system. Several models of 
endogenous purine metabolism have been developed. 
4.1.2 Computational models of endogenous purine metabolism 
An early example of modelling purine metabolism was reported by Franco 
(Franco and Canela, 1984), but at this time available computing power was a 
severe restriction on what could be feasibly modelled. They used a limited 
selection of the purine pathways in their network, and did not include DNPS or 
incorporation into DNA. A later more extensive model was created by Curto 
(Curto et al., 1997; Curto et al., 1998a; Curto et al., 1998b; Vera et al., 2007). 
Three versions of this model were developed using different types of reaction 
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kinetic schemes: 1) Generalised Mass Action (GMA), a system which uses 
power law representations of individual reaction rates; 2) s-system, a 
simplification of the GMA system which by combines inputs and outputs for 
each reaction allowing for easier analysis of the model and; 3) Complemented 
Michaelis–Menten kinetics, which uses reaction rate laws familiar to 
biochemists and pharmacologists such as Michaelis–Menten and Hill equations. 
GMA type power law equations were added to fill in the gaps where details of 
reactions were unavailable. Analysis of the three versions of the model showed 
that all of the systems were reasonably representative of the purinergic system 
provided that conditions remained within the bounds initially assumed by the 
modellers. However for larger variations to the baseline conditions of the model, 
for example large variations in levels of some enzymes, the GMA system 
proved most robust (Curto et al., 1998b). A subsequent paper showed that the 
GMA model proved useful for analysing various clinically relevant conditions 
including Lesch-Nyans disease (HGPRT deficiency) and suggested possible 
future therapies for this condition (Vera et al., 2007). The model by Curto et al 
(Curto et al., 1998b) has been uploaded to a publicly accessible database of 
computational models, the BioModels database (Chen et al., 2010).  
Of note, the Curto model (Curto et al., 1998b) has been used as a basis for a 
recent model of the action of Mizoribine, an IMPDH inhibitor (Thomas, 2010). 
This model extended the original model by Curto (Curto et al., 1998b) by 
separating nucleotides into di, mono and tri phosphate forms. This may be 
useful but it is difficult to justify given the currently available data, experimental 
techniques and the variable nature of the ratios of these species as shown by 
the qualitative but not quantitative agreement of the newly collected data of the 
individual nucleotide levels. This paper reports a new scenario that can be 
simulated using the model by Curto (Curto et al., 1998b) as a framework. 
However, it does not increase the depth of detail of the model sufficiently to 
allow conclusions to be drawn regarding the changes in nucleotide ratios as 
would be wished in a model which attempts to describe the effects of Mizoribine 
on GTP. 
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4.1.3 Aims 
1. To produce a graphical representation of the Curto model (Curto et al., 1998b) 
in Cell Designer (Funahashi et al., 2003) to aid visualisation  
2. To simulate the network using CoPaSi (Hoops et al., 2006) to verify that it 
behaves as described (Curto et al., 1998b)  
3. To further develop this model to include the metabolism of thiopurine drugs and 
in particular their interactions with the XO inhibitor allopurinol. 
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4.2 Methods 
4.2.1 SBML 
In order to facilitate the building, analysis and exchange of computational 
biological models, various standards for model representation have been 
developed. Systems Biology Mark-Up Language (SBML) (Hucka et al., 2003) is 
currently the most widely used for modelling intracellular processes and is a 
machine-readable language for representing quantitative models of biological 
systems. It is based upon the eXtensible mark-up language (XML) a pre-
existing standard. In brief, a model is defined by: its component ‘species’ 
(reactants and products), quantities for their concentration or abundance; all the 
reactions in which they interact, mathematical descriptions of reaction kinetics, 
together with related quantitative data for rate parameters. SBML is continually 
developed and released as a series of Versions and Levels with functionality 
being updated in each release.  SBML was designed to enable the easy 
exchange of models between groups and between different programmes used 
within groups. Once fully developed, a model can be analysed and simulated 
using a variety of SBML compatible programmes, such as CellDesigner and 
CoPaSi. The ability to exchange models is enhanced by the existence of a 
publically accessible database, BioModels (see below), which provides a 
curated repository of published models. These models are available for 
download in SBML format that can then be reused, modified or extended to 
allow further predictions to be made and further insights to be gained. 
4.2.2 BioModels Database 
BioModels (Chen et al., 2010) is a partially curated database of mathematical 
models of biological systems from which previously published models can be 
downloaded in a variety of formats including SBML. The model of purine 
metabolism described in Curto et al (Curto et al., 1998b) has the identifier 
“BIOMD0000000015-Curto1998_purineMetabol”. It has passed validity checks 
by BioModels staff and is stored in the curated section of the database. The 
model was downloaded using Cell Designer (Funahashi et al., 2003) (see below 
4.2.3) in the L2 V1 SBML.  
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Figure 4.1 (Previous page) Cell Designer representation of the model of 
endogenous purine metabolism (Curto et al., 1998b) downloaded from the 
BioModels database (Chen et al., 2010).  
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4.2.3 Cell Designer 4.1 
Cell Designer (Funahashi et al., 2003) (version 4.1) is a software tool with a 
particularly well developed graphical user interface (GUI) which implements an 
extension to SBML, the Systems Biology Graphical Notation (SBGN) (Nicolas 
Le Novère et al., 2009), to facilitate network visualisation. The extensions 
include additional XML to define positioning and provide defined styles to 
represent species such as genes, mRNAs, proteins and processes such as 
transcription and translation. Cell Designer is designed for the easy building, 
editing, simulating and graphical representation of dynamic computational 
models of biological systems. Cell designer was used to download the model of 
purine metabolism (Curto et al., 1998b) from BioModels Database (Chen et al., 
2010) and to export it as an SBML (Hucka et al., 2003) file for further editing in 
CoPaSi (Hoops et al., 2006) (see below 4.2.4). Cell Designer was also used to 
produce graphical representations of models in SBGN, both those downloaded 
from BioModels and those created in CoPaSi can be imported to Cell Designer 
as SBML files.  
4.2.4 CoPaSi 4.6.32 
CoPaSi (Hoops et al., 2006), derived from Complex Pathway Simulator, is a 
software tool designed to enable the building and analysis of dynamic 
biochemical models. It has a GUI that allows for the building of models without 
the need to directly write SBML but does not offer the network visualisation of 
CellDesigner. CoPaSi however, has more extensive mathematical functionality. 
It can be used to automatically create systems of ordinary differential equations 
(ODEs) from the rate laws specified for each reaction. CoPaSi also allows the 
model to be viewed as a matrix showing the stoichiometry of the defined 
reactions. CoPaSi supports SBML which allows the model to be moved easily 
between programmes. In this project the model of purine metabolism (Curto et 
al., 1998b) was imported to CoPaSi in SBML format from Cell Designer. The 
model was then altered to vary the rates of various enzymes to replicate the 
manipulations described by Curto (Curto et al., 1998b) as verification of the 
capacity of the model to replicate data from known clinical conditions (described 
below section 4.3.1). Time course simulations were run using the ODE 
deterministic (LSODA) simulator. Reactions and species were added in CoPaSi 
to the initial model to represent the metabolism of thiopurine drugs. Rate laws 
for new reactions were adapted from those described by Curto (Curto et al., 
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1998b) for the corresponding reactions of endogenous purines. These models 
were exported to Cell Designer as SBML files in order to be visualised. 
4.2.5 SBML Shorthand 
An alternative to adding reactions to the existing model of purine metabolism 
(Curto et al., 1998b) using the CoPaSi GUI, was to edit the model in SBML 
shorthand (Gillespie et al., 2006). This is a text based simplification of SBML 
(Hucka et al., 2003) which is easier for humans to read and write. The SBML 
shorthand code was translated to SBML using the web based conversion tool 
('http://www.staff.ncl.ac.uk/d.j.wilkinson/software/sbml-sh/,') or by using the 
python based mod2sbml.py tool (Wilkinson, 2010). Unfortunately, a limitation of 
SBML shorthand is that it does not support the separate definition of rate laws 
outside their reactions, which is a feature allowed in SBML. As the Curto (Curto 
et al., 1998b) model defines rate laws as separate functions outside the 
reaction, instead of as part of the reaction definition, it proved a time consuming 
process to edit the model by SBML shorthand and so final editing was done 
using the CoPaSi GUI. SBML shorthand did prove very useful for comparing 
different versions of the model to ensure that no errors were made. 
4.2.6 Analysis of endogenous purine content of cell culture cells 
The endogenous purine content, ATP, of MOLT-4 cells grown without any 
thiopurine drug treatment was analysed by LC-MS/MS in order to assess the 
utility of this data for estimating parameters of extensions to the model from 
Curto et al (Curto et al., 1998b). Cells were grown and harvested as described 
in 3.2.3 and then analysed using the LC-MS/MS method described in 3.2.5; Q1 
fragment of ATP was 508.032, Q3 was 136.200 collision energy were DP 
86.000, EP 10.000, CE 41.000 and CXP 14.000 with a retention time of 9.03 
minutes. This was compared to protein concentrations determined by the Pierce 
BCA assay described in 3.2.4. 
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4.3 Results 
4.3.1 Replication of results from Curto et al (Curto et al., 1998b) 
To assess how well the model stored in and downloaded from BioModels (Chen 
et al., 2010) (graphical representation Figure 4.1) corresponded to the model 
published in “Mathematical models of purine metabolism in man” (Curto et al., 
1998b) the manipulations described in sections 4.3, 4.4 and 4.5 (Curto et al., 
1998b) of the Curto manuscript were recreated in CoPaSi. This was important 
because the model was not originally created in SBML and therefore may have 
been altered when it was translated to SBML before uploading to the BioModels 
database. Section 4.3 of Curto et al (Curto et al., 1998b) described the effect of 
a 10-fold increase in phosphoribosyl pyrophosphate (PRPP) concentration. 
Section 4.4 (Curto et al., 1998b) described the effect of a doubling of the rate 
constant of phosphoribosyl pyrophosphate synthase (PRPPS), to simulate 
PRPPS superactivity. Section 4.5 (Curto et al., 1998b) described the effect of a 
100-fold reduction in the rate constants of HGPRT activities with respect to HX 
and guanosine (HPRT and GPRT) to simulate HGPRT deficiency. As shown in 
Figure 4.2 a and b the model simulated in CoPaSi behaved as the models 
described in Curto et al (Curto et al., 1998b)  in response to a 10-fold increase 
in PRPP with regards to IMP and xanthine. Both initially increase and then 
decrease back to the baseline level. IMP increases from 98 to 109 µM in the 
model in CoPaSi. In the GMA model in the paper IMP is shown to increase 
slightly more, to around 119 µM. In both cases the concentration of IMP has 
reduced back to 98 µM by around 100 minutes. HX increases from 9.5 to 11.5 
µM in the model version in CoPaSi and returns to its initial value after 100 
minutes. The GMA version is shown to decrease slightly then to increase to 
slightly below 12 µM and to return to steady state, as reported by Curto et al 
(Curto et al., 1998b). The fit is not perfect but is qualitatively similar in that both 
the downloaded and the reported models rapidly return to normal values for IMP 
and HX concentration after increasing the initial concentration of PRPP. 
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b 
 
Figure 4.2 CoPaSi time course output showing the effect of a 10-fold increase 
in PRPP concentration at time 0 on a IMP in blue b Hx in yellow. 
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Increasing the activity of PRPPS two fold in a CoPaSi time course simulation 
(Table 4.1) had the same effect as described in Curto et al (Curto et al., 1998b) 
(shown in Table 8 in Curto et al (Curto et al., 1998b)). PRPP concentration, 
Vden flux, (the rate constant used by Curto et al to describe DNPS) Xa, (the 
designation in Curto et al of xanthine concentration) and Ua (the designation in 
Curto et al of UA concentration) all increased by the same amount in both the 
published version of the GMA model and the model as simulated in CoPaSi. 
This was generally less than the clinical data shown in Curto et al (Curto et al., 
1998b). Hx_ino_dino (a species in the model described by Curto et al (Curto et 
al., 1998b) including HX, inosine and deoxyinosine concentrations), increased 
slightly less in the CoPaSi version than HX is described as doing; this is simply 
due to the fact that the authors of the paper disaggregated this value before 
reporting only HX to make it comparable to the reported clinical data. Both 
models slightly underestimate the clinical data with regards to changes to PRPP 
and UA but overestimate the effect of PRPPS activity on HX. However, as the 
model downloaded to CoPaSi was intended to replicate the model from Curto et 
al (Curto et al., 1998b), it would be inappropriate to expect the CoPaSi version 
of the model to compare better to clinical data than the model it was based on 
as no further model improvements or validation had been carried out. 
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Initial 
Value 
CoPaSi Mean 
of 100 
minutes 
GMA 
Curto 
(Curto et 
al., 
1998b) 
Clinical data as 
reported in Curto 
et al (Becker et al., 
1989; Jimenez et 
al., 1989; Curto et 
al., 1998b) 
PRPP μM 5.00 7.80 7.80 13-29 
Vden μmoles / 
minute 
2.39 4.70 4.70 4.7-12.4 
Hx_ino_dino 
μM 
10.00 40.30 41.00 30 
Xa μM 5.00 14.80 15.00 10 
Ua μM 100.00 131.00 131.00 300 
 
Table 4.1 The outcome of increasing PRPPS activity 2-fold both in the model in 
CoPaSi and that previously reported by Curto et al(Curto et al., 1998b)  
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 Reducing HGPRT activity increased the concentrations of Hx_ino_dino, Gua 
and UA (Table 4.2), the substrates for HPRT, GPRT and the product of an 
alternative reaction of Hx_ino_dino. This output compares well with Table 9 of 
Curto et al (Curto et al., 1998b) and also the reported clinical data (last two 
columns of Table 4.2). The values reported by Curto et al (Curto et al., 1998b) 
for a new steady state with reduced HGPRT activity were all matched by the 
mean value for 100 minutes when the model in CoPaSi is simulated as a time 
course with altered HGPRT activity. Due to the fact that the quantity of excreted 
metabolites (such as UA) accumulate in the downloaded model, the reactions 
which represent excretion create new species in the model and steady state 
cannot be reached as the model structure does not have outputs which can 
equal the inputs. For this reason steady state values cannot be analysed, so an 
alternative way of assessing these values was used; the mean value of each 
species over 100 minutes of model time were used to represent an 
approximation of steady state, given this the data match well. 
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Initial 
Condition 
CoPaSi GMA 
mean of 100 
minutes 
GMA 
Curto 
(Curto et 
al., 
1998b) 
Clinical Data 
Shown by 
Curto et al 
(Seegmiller 
and 
Rosenbloom, 
1967; 
Harkness, 
1989; 
Fujimori et 
al., 1991; 
Curto et al., 
1998b) 
PRPP μM 5.00 7.14 7.10 - 
Hx_ino_dino μM 10.00 69.81 70.60 71 
Xa μM 5.00 22.55 22.50 15 
Gua μM 5.00 9.62 9.00 - 
UA μM 100.00 145.47 145.70 150 
Vgua 
μmoles/minute 
1.10 1.53 1.47 - 
Vhxd 
μmoles/minute 
1.23 4.35 4.40 - 
Vxd μmoles/minute 2.30 5.27 5.30 7-14 
Vhx μmoles/minute 0.05 0.44 0.44 0.45 
Vx μmoles/minute 0.03 0.61 0.60 0.27 
Vua μmoles/minute 2.30 5.27 5.30 7-14 
 
Table 4.2 The effects of decreasing the rate constants of HPRT and GPRT 100-
fold in CoPaSi compared to the original model data from the simulation in 
CoPaSi and from Curto et al (Curto et al., 1998b) 
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4.3.2 Adding reactions of thiopurine metabolism to the model of purine 
metabolism 
Reactions of thiopurine metabolism were added to the existing model of 
endogenous purine metabolism to produce a model shown in Figure 4.3, using 
the GMA type kinetic laws. The initial assumption was that all thiopurine 
reactions would be modified by endogenous metabolites and thiopurine 
metabolites and that all thiopurine metabolites behaved in the same way as 
their analogues. However this led to rate laws with many parameters that could 
not be defined with any confidence using data from the literature or experiments 
performed in this project. It was therefore decided that thiopurine substrates 
would be included in the rate law and that endogenous substrates will only act 
as modifiers in the same manner that they act on analogous endogenous purine 
reactions. Constants were unknown in the methylation reactions iTPMT, gTPMT 
and mpTPMT, and they were initially set to the default value 0.1. Thiopurine 
metabolites had an initial concentration of 0, except external MP to simulate 
drug being added to untreated cells. 
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Figure 4.3 (Previous page) A graphical representation from CellDesigner of a 
version of a model combining thiopurine and endogenous purine metabolism 
with the purine metabolism following the Curto model. Endogenous purines 
shown in blue equivalent to the reactions shown in Figure 4.1, thiopurine 
metabolites; TIMP, TX, TUA, TXMP, TGMP, deoxyTGNs, TGNs in DNA and 
TGNS in RNA shown in red and thiopurine drugs MP and AZA shown in purple. 
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The GMA rate law (Figure 4.4) includes a rate constant, atgmps. This is 
multiplied by the concentration of the substrates or modifiers TXMP and ATP 
multiplied by the size of their compartment, in this case 1. Each concentration is 
raised to a power which indicates their effects, ftgmps7 and ftgmpsa. A positive 
number greater than 1 is an activator. A negative number or a fraction indicates 
an inhibitor (Voit and Savageau, 1987; Curto et al., 1997). This type of rate law 
is not appropriate for species with a concentration of 0 as it produces the value 
infinity in the case of a negative power as shown in Table 4.3. This model was 
therefore rejected as GMA was unsuitable to model a time course following 
addition of MP to cells. This rejection was further supported by the fact that few 
parameters of the GMA rate laws could be established from the literature 
leaving many parameters unassigned making successful parameter estimation 
from data more difficult. 
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atgmps ∗ (tXMP ∗ default)^ftgmps7 ∗ (ATP ∗ default)^ftgmpsa/default 
 
Figure 4.4 GMA type kinetic law for tGMPS from model of combined 
endogenous purine and thiopurine metabolism. 
 
 
 
 
# Time ["thio GTP_GDP_GMP"] 
0 0 
0.72 -1.#IND 
1.44 -1.#IND 
2.16 -1.#IND 
2.88 -1.#IND 
3.6 -1.#IND 
 
Table 4.3 An extract of data from a combined model of endogenous and 
thiopurine metabolism for combined TGN concentrations after time course 
simulation with thiopurine metabolites with an initial concentration of 0 using 
GMA kinetic laws an infinite value error message is displayed in column 2, this 
was true for all thiopurine metabolites 
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4.3.3 Variability of endogenous purines in cell culture samples as 
measured by LC-MS/MS 
As described in Chapter 3 there was a great deal of variability in the levels of 
the endogenous purines measured by LC-MS/MS, ATP and GTP. This may be 
due to the fact that these measurements were made during method 
development before the importance of the temperature at which buffers were 
prepared was recognised, although they were variable even by comparison to 
thiopurine metabolites measured at the same time. Due to this variability the 
data concerning ATP and GTP would not be of sufficiently high quality to be 
used to estimate the inhibition constants needed to model the inhibition of the 
combination of reactions representing DNPS in the Curto model (Curto et al., 
1998b), by meTIMP. Therefore, the model finally built for this project was 
restricted to thiopurine metabolism. There was a great deal of variability in the 
amount of ATP detected by this LC-MS/MS method in MOLT-4 cells (Figure 
4.5) with ATP levels normalised to protein concentration varying between 
samples grown under the same conditions. This may be due to the fact that this 
method is not optimised for separation of ATP from other chemicals with similar 
characteristics or because cells rapidly use ATP when stressed, as they may be 
during harvest. These data reinforced the fact that the model should deal only 
with thiopurines. 
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Figure 4.5 Bar chart showing ATP normalised to protein in cultured cells grown 
without MP. 
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4.4 Discussion 
4.4.1 Comparison of the model as downloaded from BioModels database 
with the description of the model in Curto et al. (Curto et al., 1998b) 
The version of the model of purine metabolism (Curto et al., 1998b) downloaded 
from BioModels database (Chen et al., 2010) (Figure 4.1) behaves as reported 
for the original version. It was able to replicate up to 100-fold variation in some 
reaction parameters and a 10-fold variation in the concentration of some 
species (Figure 4.2, Table 4.1 and Table 4.2). This also suggests that this 
model can replicate clinical effects of alterations in purine metabolism. 
One difference between the model as published and the model as downloaded 
from BioModels database was that the model as published did not include the 
concentrations of species leaving the model, the products of excretion reactions 
or reactions which join other parts of cellular metabolism that use purines. 
Therefore in the downloaded version of the model these species are counted 
and constantly accumulate. This prevents a steady state analysis being run, 
which in turn prevented a full comparison with the model as previously 
described. 
4.4.2 Suitability of power law kinetics 
It has also been demonstrated that the GMA power law kinetic rate law is 
unsuitable for models in which the concentration of some species can become 0 
(Table 4.3). This presents a problem as the model of thiopurine metabolism is 
intended to model a time course beginning with the addition of drug, when the 
metabolites of MP are at a concentration of 0. This type of model also requires 
many parameters for which data are lacking. 
4.4.3 Measurements of endogenous purines 
There were several important links between thiopurine metabolism and 
endogenous purine metabolism. MeTIMP inhibits DNPS; MTAP, an enzyme of 
adenosine salvage, alters the sensitivity of cell culture cells to thiopurines and 
alters the activity of TPMT. Also it is possible that there may be competition 
between thiopurines and endogenous purines for any enzymes that are at low 
concentrations. To use a combined model of purine and thiopurine metabolism, 
such as the one shown in Figure 4.3, to study these effects it would be 
necessary to estimate the kinetic constants representing these interactions and 
this would require experimental data about the effects of thiopurine treatment on 
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endogenous purine metabolism and vice versa to be collected. However the 
LC-MS/MS method was unable to reliably detect ATP (Figure 4.5), GTP or any 
other endogenous purine. Furthermore the MTAP reaction is not explicitly 
included in the Curto model (Curto et al., 1998b) and therefore, without further 
data, it would be difficult to model the effects of MTAP deficiency on the 
concentrations of purines or thiopurines. As described above, detailed 
modelling of enzymatic reactions requires information about the concentrations 
of the enzymes and any co-factors, data that are not available in the literature. 
For these reasons a combined model of endogenous purine and thiopurine 
metabolism is unlikely to be successfully parameterised and validated at this 
stage. 
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4.5 Conclusions 
The version of the model of purine metabolism developed by Curto et al (Curto 
et al., 1998b) and downloaded from BioModels database (Chen et al., 2010) 
was largely able to replicate the reported output with regards to several 
manipulations of both the initial values of species and of the rates of several 
reactions (Figure 4.2, Table 4.1 and Table 4.2). The rate law used in this model 
was unsuitable to model the metabolism of MP.  
There were insufficient data available in the literature about the interactions of 
endogenous purine metabolism and thiopurine metabolism to be able to create 
and validate a combined model. The LC-MS/MS method developed during this 
project was not capable of producing data to inform this part of the model. For 
these two reasons a model of thiopurine metabolism alone was developed 
further, and this model is presented in Chapter 5. 
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Chapter 5. Building a model of thiopurine metabolism and 
using it to understand the mechanisms of the interaction 
between allopurinol and thiopurine metabolism 
5.1 Introduction 
5.1.1 Previous models of thiopurine metabolism 
There have been two previous attempts at modelling different aspects of 
thiopurine metabolism and toxicity. One is a pharmacokinetic model of AZA 
metabolism and the other is a small scale dynamic model of the effects of MP 
on the viability of cells (Fransson et al., 2006; Panetta et al., 2006; Fransson et 
al., 2007).  
The model of the pharmacokinetics of thiopurines deals with the initial period 
after initiating AZA treatment. This model uses pharmacokinetic equations to 
represent the passage of the drug and metabolites through different tissues of 
the body and mass action kinetic equations to represent the action of 
metabolising enzymes on the thiopurines. The ultimate aim of this model was to 
predict the optimum dose needed to produce adequate levels of TGNs in a 
patient without producing too many methylated metabolites. However the model 
was unable to fit the data from the initial group of patients (Fransson et al., 
2006; Fransson et al., 2007). The authors speculated that because there were 
only data available about two metabolites in one tissue this did not allow 
adequate fitting of a model which included reactions involving transport between 
several tissues and reactions of many other metabolites. 
The other previous model of thiopurines was a model of the effects of TGN 
incorporation on cell viability (Panetta et al., 2006). Data from three cell lines 
with different sensitivities to MP were fitted to the model and the estimated 
kinetic parameters for different reactions were compared. The cell culture data 
indicated that the difference in sensitivity to thiopurines between the cell lines 
was not due to their ability to incorporate TGNs into DNA. The model suggested 
that it was likely due to differences in their ability to progress through the cell 
cycle after incorporation of TGNs into DNA. This was confirmed by gene 
expression analysis showing altered levels of expression of genes known to be 
involved in control of the cell cycle (Panetta et al., 2006). 
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5.1.2 XO Inhibitors 
The XO inhibitor allopurinol is used clinically in combination with AZA to 
optimise the ratio of TGNs to methylated thiopurine metabolites (Sparrow et al., 
2005; Leung et al., 2009; Brackett et al., 2014). The mechanism of this 
optimisation is poorly understood, it would be expected that if XO inhibition, 
blocking excretion of MP via TX and TUA, was the only effect of allopurinol, 
then all metabolites would increase, thus maintaining the same ratio of TGNs to 
methylated thiopurine metabolites. In contrast, clinical data (Sparrow et al., 
2005; Leung et al., 2009; Brackett et al., 2014) indicate that with allopurinol, 
levels of methylated metabolites are reduced whilst TGNs increase. To explain 
this unexpected effect, it has been suggested that allopurinol might inhibit 
TPMT, possibly via TX (Blakera et al., 2012); this has been shown to occur in 
RBC lysates but has not been demonstrated in vivo (Seinen et al., 2013a). It 
has also been suggested that allopurinol may increase the activity of HGPRT 
although it has not been shown whether this is via an increase in HGPRT 
expression or via an activating interaction of allopurinol with the enzyme. A 
computational model of thiopurine metabolism will allow the consequences of 
various mode of allopurinol action to be assessed and facilitate the design of 
experimental tests to establish the mechanism of interaction of allopurinol with 
thiopurine drugs.    
5.1.3 Aims 
1. To develop a model able to fit previously available and newly generated data 
about thiopurine drug metabolism, specifically MP using cell culture 
samples.  
2. To generate quantitative data from a time course of MP sensitive cells 
treated with MP to inform and validate a model of MP metabolism. 
3. To expand the model to include potential interactions of allopurinol with MP 
drug metabolism, to attempt to explain the decreased sensitivity to MP of 
cells also treated with high concentrations of allopurinol and increased 
sensitivities to MP with cells treated with low concentrations of allopurinol 
and if possible the effect of allopurinol on methylated metabolite to TGN 
ratios seen in clinical data. 
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5.2 Methods 
5.2.1 Growth and analysis of cell culture cells with MP 
MOLT-4 cells were grown as described in 2.2.1. 
Cells were seeded at 5x105 cells/mL in 75 mL total initial volume for the MP-
only time course and 80 mL total initial volume for allopurinol plus MP, 24 hrs 
before the time course experiment to recover from seeding and to reach 1x106 
cells/mL. 
At the beginning of the experiment (t=0) a 6 mL aliquot of cells was removed, 
washed in PBS, split into two and snap frozen. 
Drug was then added to cell culture dissolved in 0.1 M NaOH and medium to 
give a final concentration of 10 µM MP with 250 µM allopurinol or 1 mM 
allopurinol alone (from stock solution described in 2.2.3). 
At 2, 4, 6, 8, 10 and 24 hours after addition of drug 6 mL aliquots of cells were 
removed, washed in PBS, split into two and snap frozen. When the experiment 
was repeated with allopurinol as well as MP technical replicates were omitted 
from LC-MS/MS analysis. 
Cells were stored at -80 ͦ C until analysis by LC-MS/MS with results normalised 
to sample protein concentration. Linear regression was performed on the peak 
areas of the standards for each analyte and the sample values calculated using 
the intercept and gradient found for each analyte and the detected peak area. 
The concentration was then normalised to protein concentration in the cell 
lysate, as determined by Pierce BCA assay described in 3.2.4. 
5.2.2 CoPaSi 4.6.32 
A model of MP metabolism was developed in CoPaSi (Hoops et al., 2006) a 
programme for building and editing biological models described in section 4.2.4. 
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5.3 Results 
5.3.1 Cell culture data with MP alone 
As shown in Figure 5.1 after treatment with 10 μM MP alone concentrations of 
meTIMP,DP and TP, meTGMP, DP and TP and TGMP, DP and TP increased 
throughout the 24 hours of the time course whilst the TIMP concentration 
increased initially before reaching a plateau or beginning to decrease at 10 h. 
MP increased initially before reaching a plateau after approximately 2 h.  
Variation was generally greater between biological replicates than between 
technical replicates (Table 5.1). Metabolites detected at higher levels such as 
TIMP were less variable than those nearer their limit of detection, for example 
meTGMP,DP,TP. Technical replicates were only occasionally more than 50% 
and were mainly less than 20% whereas biological replicates often varied by 
more than 50%.  
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Figure 5.1 a-e Graphs showing the mean (points [n=3 biological replicates]) 
and 1 SD of the concentrations of metabolites of MP normalised to protein 
concentration from MOLT-4 cells cultured with 10 µM MP a MP, b TIMP c 
TGMP, TGDP and TGTP summed, d meTGMP, meTGDP and meTGTP 
summed, e meTIMP, meTIDP and meTITP summed.  
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Analyte 
Range of % co efficient 
of variation of 
biological replicates 
Range of % co efficient 
of variation of 
technical replicates 
TIMP 55-109 1-73 
MP 34-101 12-118 
TGMP,DP,TP 23-73 1-88 
meTIMP,DP,TP 28-58 4-88 
meTGMP,DP,TP 18-167 1-141 
 
Table 5.1 The percentage co-efficient of variation between different repeats of 
MOLT-4 cells grown with MP. 
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5.3.2 Initial model development in CoPaSi 
This model was developed in CoPaSi (Hoops et al., 2006) with all reactions and 
species defined ab initio. The reactions included were those described in 
Figure1.2 that relate to MP. Initially the reduction of TGMP by GMP reductase 
was also included however evidence suggests that TGMP is not a substrate for 
this enzyme (Spector et al., 1979). The model assumed Michaelis–Menten 
kinetics (Michaelis and Menten, 1913; Johnson and Goody, 2011) for most 
reactions. Michaelis-Menton kinetics is an approximation of enzyme substrate 
binding and product release which assumes an excess of enzyme relative to the 
concentration of substrate. Michaelis-Menten kinetics does not take account of 
any inhibition or activation by substrates, products, co-factors or competitive or 
allosteric modifiers. This reduces the number of parameters in the model 
compared to rate laws used in the earlier model described in Chapter 4 and as 
there were limited data available about the rate laws appropriate to thiopurine 
metabolism, this was an appropriate simplification.  
Km values for the various enzymes were obtained from the literature; where a 
Km for a thiopurine metabolite was unavailable, it was assumed to be three 
times larger than that of the endogenous metabolite (affinity reduced to one 
third the endogenous affinity). This was approximately the case for XO in 
relation to TX in a study in which both values were reported (Kudo et al., 2010). 
Initial Km values are listed in Table 5.2. 
The only exception to this was incorporation of thioguanosine into DNA as this 
represents several steps the intermediates of which were not measured. This 
was modelled using a mass-action rate law, assuming the reactions to be 
dependent on the availability of TGNs and nothing else. 
Values were transformed to internal cell concentration in µM based on a cell 
volume of 2 pL (2e-12 L) and 100 µg protein per cell (Rodríguez-Caso et al., 
2006) except for MP_out which was placed in a separate compartment of 
volume 0.07 L. 
All species values except MP_out, the concentration of MP present in the 
medium were initially defined as 0 and MP_out was initially defined as 10 µM, 
as this was the concentration of MP incubated with cells. 
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Parameter Initial Value (If 
derived from 
literature) 
Value 
estimated from 
mean data 
Value estimated 
from separated 
biological 
replicates 
K1 DNA 
incorporation 
(1/min) 
 0.04 0.0281434 
Km GMPS (µ 
mol/L) 
12.00(3.6 X 3) 
(Spector, 1975)  
68558e+13 1.80643e+12 
Vmax GMPS(µ 
mol/(L*min) 
 3.53686e+11 1.06985e+10 
Km HGPRT I (µ 
mol/L) 
18.80 (Lennard et al., 
1993) 
548.22 635.22 
Vmax HGPRT I (µ 
mol/(L*min) 
 0.09 0.09 
Km HGPRT G (µ 
mol/L) 
18.80 18.80 18.80 
Vmax HGPRT G(µ 
mol/(L*min) 
 43.25 39.29 
Km IMPDH(µ 
mol/L) 
135.00 (45 X 3) 
(Yamada et al., 1990) 
4815.39 28977.90 
Vmax IMPDH(µ 
mol/(L*min) 
 20.00 99.98 
Km MP uptake(µ 
mol/L) 
14.21(Katsuhito et 
al., 2007) 
0.12 1.06 
Vmax MP uptake(µ 
mol/(L*min) 
 1.79258e-11 1.54676e-11 
Km TPMTMP(µ 
mol/L) 
10.60 (Krynetski et 
al., 1995) 
10.60 10.60 
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Vmax TPMTMP(µ 
mol/(L*min) 
 9.77 8.019 
Km TPMPTtGMP 
(µ mol/L) 
27.10 (Krynetski et 
al., 1995) 
27.10 27.10 
Vmax TPMTtGMP 
(µ mol/(L*min) 
 0.0014 0.0015 
Km 
TPMTtIMPuptake(µ 
mol/L) 
25.70 (Krynetski et 
al., 1995) 
25.70 25.70 
Vmax TPMTtIMP (µ 
mol/(L*min) 
 0.086 0.089 
Km XOMP (µ 
mol/L) 
4.97 (assumed 
equal to XOtX)  
2.50 2.50 
Vmax XOMP (µ 
mol/(L*min) 
 1.14 1.14 
Km XOtX (µ mol/L) 4.97 (Kudo et al., 
2010) 
4.97 4.97 
Vmax XOtX(µ 
mol/(L*min) 
 0.37 0.37 
 
Table 5.2 (previous page) Values of parameters as determined from the 
literature (column 2), by parameter estimation using CoPaSi and the mean of 3 
biological and 2 technical replicates (6 total) (column 3), and each biological 
replicate as a separate experiment with 2 repeats (column 4). 
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V max values were determined using the parameter estimation tool in CoPaSi. 
The initial values were determined by approximately replicating the cell culture 
data by manipulating the V max values manually beginning at 0.1. This was 
followed by using the Parameter Estimation facility in CoPaSi. The random 
search, evolutionary programming, particle swarm and Hooke and Jeeves 
algorithms from CoPaSi were used and the model was updated after each run. 
The Hooke and Jeeves algorithm is a direct search algorithm. It does not rely on 
differentiation, but instead on an iterative calculation of the value of the function 
of the differences between data and the model. Evolutionary programming 
creates a population of possible parameter sets; each parameter is equivalent 
to a gene, these are then each compared to several others allowing individuals 
to be ranked and the worst are eliminated. Small random changes, or 
mutations, are made and the new population is then re-ranked; after a number 
of iterations the best genome is selected. The random search algorithm 
generates random parameter sets and compares them to the desired outcome; 
given unlimited iterations this algorithm will produce an ideal solution. The 
particle swarm method begins with a swarm of possible parameter sets or 
particles these are altered to change the position of the particles in the 
parameter space; these solutions are then compared and the best position is 
updated, eventually this may lead to the optimal parameter set being found, 
although a local optimum may be found instead. Runs were performed 
iteratively until no further reduction in the sum of squares was seen; if one of the 
parameters had reached its boundary, the range for that parameter was 
extended and the estimation run again. As this strategy did not result in a good 
fit alone, Km values for GMPS, IMPDH, MP uptake, XOMP and HGPRT were 
also allowed to vary; each was added in turn to the list of parameters to be 
estimated when no improvement in model fit, compared to data from cultured 
cells, was seen. These parameters were chosen to vary for a variety of reasons; 
GMPS and IMPDH were allowed to vary first as the Km values reported for 
these were for endogenous purines, MP uptake was based on the Km of only 
one transporter not all possible transporters, XOMP was based on data for XO 
with TX not MP, and HGPRT was based on data from RBCs not MOLT-4s. 
Data used for parameter estimation with CoPaSi were time course data from 
cells grown with 10 µM MP for 24 hours and then analysed using LC-MS/MS as 
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described above. Constraints were also placed upon the parameter estimation, 
an option available in the CoPaSi parameter estimation tool. These were that 
TGMP<TXMP<TIMP as this had previously been described under the similar 
conditions by a group able to measure TXMP (Zimm et al., 1985). Also, models 
that did not fulfil the condition that at early time points TIMP should be 
substantially higher concentration than TUA (Kalra et al., 2007) were rejected 
after a time course simulation had been run. Parameter estimations were run 
with the data either entered as three separate experiments, each with two 
repeats representing technical replicates, or with a mean of all replicates. 
Time course data were produced using the deterministic (LSODA) simulator in 
CoPaSi. Time course data were obtained for the model with 10 µM MP. An 
extra parameter was added to the model to simulate changes in TPMT activity. 
Time course simulations were run to compare this model against data from two 
published papers describing knock down or increased TPMT activity (Coulthard 
et al., 2002; Misdaq et al., 2012). Time courses were also simulated with 10 µM 
MP and varying levels of TPMT activity. 
A graphical representation of the model is shown in Figure 5.2 and SBML of the 
model is in appendix a.  
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Figure 5.2 Graphical representation of the initial model of MP metabolism without 
allopurinol as produced in Cell Designer from SBML imported from CoPaSi. Thiopurine 
metabolites or groups of metabolites measured by LC-MS/MS used in parameter 
estimation are highlighted by bold edging.  
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5.3.3 Parameter Estimation in CoPaSi of the model of MP metabolism 
The SBML of this model is included in appendix a. Parameters were estimated 
in CoPaSi using data collected in two ways. Firstly, with the mean of all six 
replicates defined as one experiment CoPaSi (final parameters shown in Table 
5.2 column 3). Secondly with the three biological replicates defined as three 
experiments with two replicates each in CoPaSi (final parameters shown in 
Table 5.2 column 4). Most parameters values were similar for the two methods 
of parameter estimation. However, GMPS Km and Vmax, IMPDH Km and 6-MP 
uptake Km all varied by 10 fold or more. The two variants of the model 
(informed by the two methods of parameter estimation) produced similar time 
course results (Figure 5.3 a and b compared to c and d). This similarity 
suggests that the most variable parameters are insensitive to change. 
The model output and cell culture data are compared in Figure 5.3 b and d. The 
value reached for sum of squares of the parameters estimated from the mean 
data was 24.47.The value for sum of squares with the data separated by 
biological replicate was 1619.00. This is a much poorer fit probably due to the 
fact that the data loaded to CoPaSi was much more variable. 
Due to the similarities of the model variants in terms of time course output and 
parameter values, and the better progress of fit value of the model variant 
estimated using the mean, all further investigations only used the model as 
parameterised using mean data.  
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Figure 5.3 a-d (previous 2 pages) Graphs showing metabolite concentration 
data from MOLT-4 cells grown with 10 µM MP adjusted to µM  inside cells 
mean as points with bars showing 1 SD (n= 3) and lines showing the output of 
simulations of the computational model of MP metabolism. Green TIMP, dark 
blue meTIMP,meTIDP and meTITP summed, black MP, red TGMP, TGDP and 
TGTP summed and pale blue meTGMP, meTGDP and meTGTP, pink meMP 
(model), yellow TXMP (model), grey TX (model), black TUA (model) and red 
TGNs in DNA (model). a Model output from model calibrated using mean data 
showing only those metabolites measured in cell culture, b Model output from 
model calibrated using mean data showing all metabolites included in the 
model, c Model output from model calibrated using repeated data as separate 
experiments showing all metabolites, d Model output from model calibrated 
using repeated data as separate experiments showing only those metabolites 
measured in cell culture. All units μM and minutes. 
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5.3.4 Response of the model of MP metabolism to variation in TPMT 
activity 
Coulthard et al. (2002) describe the effect of a 3.8 fold increase in TPMT activity 
on the levels of methylated thiopurine metabolites and  TGNs in DNA after 
incubation with equitoxic doses of MP (1.8 µM for cells induced to increase 
TPMT activity, 8 µM for normal cells). The paper showed that the level of 
meTIMP was increased but not significantly in cells with induced TPMT 
compared to uninduced cells treated with equitoxic doses of MP. This suggests 
that the effect of TPMT activity in the model may be too great with respect to 
meTIMP as the increase in the model under these circumstances is 68%, 
shown in (Figure 5.4b). The decrease in TGNs in DNA reported by Coulthard et 
al (Coulthard et al., 2002) and that in the model are more similar in magnitude 
(Figure 5.4a).  
Misdaq et al (2012) describe the effects of reducing TPMT activity from 6.1 
U/mg protein to 1.7 U/mg protein. This paper describes the effects of incubating 
TPMT knockdown and wild type Jurkat cells with 4.6 and 4.7 µM MP on TGNs 
and meMP. TGNs decreased, although not significantly, in the cells however, in 
the model they increase by 279% (Figure 5.4c). meMP decreased by 95% in 
Jurkat cells with knocked down TPMT compared to 62% in the same 
experiment in the model (Figure 5.4d). This suggests that with respect to the 
effect on TPMT inhibition the model is able to replicate data qualitatively from 
another cell line for meMP but not TGN concentration. 
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b 
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d 
Figure 5.4 a-d (previous 2 pages) Showing existing data from papers compared to 
time course simulations from the model of thiopurine metabolism calibrated in CoPaSi. 
Data expressed as relative values to those with normal TPMT activity effects of a 
increasing TPMT activity on TGNs in DNA b increasing TPMT activity on methylated 
thioinosinic nucleotides c decreasing TPMT activity on TGNs d decreasing TPMT 
activity on methylated thioinosinic nucleotides. 
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5.3.5 Culture of cells with allopurinol and MP 
In the presence of either 1 mM or 250 µM allopurinol with 10 µM MP there was 
a lower concentration of all metabolites measured (Figure 5.5b-e), except for 
MP (Figure 5.5a), than there was when cells were grown with 10 µM MP alone. 
There was no reduction in the ratio of meTIMP, meTIDP and meTITP to TGMP, 
TGDP and TGTP at time points up to 24 hours. 
5.3.6 Expansion of the model to include interactions between allopurinol 
and MP 
This model was adapted to represent possible effects of allopurinol on MP 
metabolism as shown in Table 5.3 and Figure 5.6. Allopurinol was assumed to 
act as a competitive inhibitor of XO. It was proposed that allopurinol was also a 
competitive inhibitor of HGPRT and, or MP uptake, as both it and MP are 
analogues of HX and the data from cells grown with allopurinol showed a 
reduction in the concentrations of MP metabolites. HGPRT activity has been 
shown to be induced by use of AZA combined with MP; however this may be 
due to induction of HGPRT expression after competition for the enzyme. It was 
also proposed that TPMT may be inhibited by TX which may increase after 
allopurinol treatment; this follows mechanistic reports in the literature. Each 
interaction was modelled using the competitive inhibition rate law pre-defined in 
CoPaSi; 8 versions of the model representing different combinations of these 
reaction were created (Figure 5.6 and Table 5.3).  
115 
 
a 
 
 
b  
 
 
 
116 
 
c  
 
 
d  
117 
 
e 
 
Figure 5.5 a-e Graphs showing the mean (points [n=3 biological replicates]) 
and 1 SD of the concentrations of metabolites of MP normalised to protein 
concentration from MOLT-4 cells cultured with 10 µM MP a MP, b TIMP c 
TGMP, TGDP and TGTP summed, d meTGMP, meTGDP and meTGTP 
summed, e meTIMP, meTIDP and meTITP summed.  
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Model/Affected 
Reaction 
XO 
TPMT (by 
TX) 
HGPRT MP Uptake 
A X X X  
B X X  X 
C X  X X 
D X X   
E X  X  
F X   X 
G X    
H X X X X 
  
Table 5.3 Showing the proposed reactions of allopurinol on MP metabolism, X 
shows an inhibition included in the relevant version of the model. 
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Figure 5.6 Graphical representation of the model variants showing the proposed 
effects of allopurinol on MP metabolism in red, which combinations of the interactions 
shown in red is included in each model variant is described in Table 5.3. 
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5.3.7 Parameter estimation in model variants with and without allopurinol  
Parameter estimation, beginning with the model as developed for MP alone was 
performed as above, including the Ki’s for each of the proposed reactions and 
the Km and Vmax of allopurinol uptake. The data used were from cell culture 
cells grown with 10 μM MP with either 1 mM allopurinol or 250 μM allopurinol. 
Parameter estimations were carried out by fitting the mean of three biological 
replicates for each of three treatments (0 allopurinol plus MP, 1 mM allopurinol 
plus MP and 250 μM allopurinol plus MP). 
All versions of the model were then simulated with initial concentrations of 10 
μM MP and either 0, 1 mM, 250 μM or 100 μM allopurinol. 
All 8 versions of the model, with variants on the possible interactions of 
allopurinol with MP metabolism specified in Table 5.3, were unable to 
simultaneously fit the three data sets, 10 μM MP alone and in combination with 
either 250 μM allopurinol or 1 mM allopurinol. The minimum value of sum of 
squares reached were; A 105, B 118, C 105, D 107, E 109, F 106, G 109, and 
H 108. These values are all similar but A (allopurinol inhibiting XO and HGPRT 
and TX inhibiting TPMT), and C (Figure 5.7) (allopurinol inhibiting XO, HGPRT 
and MP uptake) had slightly better fits than the rest.  
All of the models had problems fitting the 10 μM MP with 1 mM allopurinol with 
respect to the sum of TGMP, TGDP and TGTP. The inhibition of the production 
of these metabolites by allopurinol at high levels was too great resulting in very 
low values. At 250 μM allopurinol with MP only C was able to produce 
appropriate concentrations of the sum of TGMP, TGDP and TGTP at 250 μM 
allopurinol with MP (Figure 5.8). Model C also showed a higher concentration of 
the sum of TGMP, TGDP and TGTP when a time course was simulated with the 
combination of 10 μM MP and 100 μM allopurinol than with 10 μM MP and 1 
mM allopurinol all reaching similar concentrations to 10 μM MP with no 
allopurinol (Figure 5.9). This presents another suggestion that this may be a 
reasonable model as TGNs are active MP metabolites and as 100 μM 
allopurinol increases the sensitivity of cells to MP whereas 1 mM allopurinol 
decreases the effects of MP. However, model C predicts lower meTIMP, 
meTIDP and meTITP in cells treated with higher allopurinol concentrations with 
MP; given that these metabolites are also cytotoxic, yet cells treated with 
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combination of drugs are less sensitive than cells treated with MP and lower 
concentrations of allopurinol, this may be less likely.  
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c 
Figure 5.7 (previous 2 pages) Graphs showing the results for each measured 
metabolite from cultured cells point  mean and bars 1 SD (n=3) at a 0, b 250 
and c 1000 µM allopurinol with 10 µM M with time course simulations for each 
drug combination by model C as lines. For each section metabolites are as 
follows black MP, green TIMP, red TGMP,TGDP,TGTP combined, blue 
meTIMP, meTIDP and meTITP combined and pale blue meTGMP, meTGDP 
and meTGTP. 
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Figure 5.8 TGMP, TGDP and TGTP data from cultured cells points (mean n=3) 
and simulation of all model variants with 10 µM MP and 250 μM allopurinol, only 
data from cultured cells and model c (blue) visible. 
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Figure 5.9 TGMP,TGDP and TGTP data from cultured cells points (mean n=3) 
and simulation of model variant C as lines data created using 10 µM MP with 1 
mM allopurinol (green), 100 μM allopurinol (blue model only), 250 μM 
allopurinol (red) or no allopurinol (black) all units μM and minutes. 
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5.4 Discussion 
5.4.1 LC-MS-MS analysis of cell culture data 
The LC-MS-MS method developed in Chapter 3 detects thiopurine metabolites 
in both PBMCs and RBCs from patients treated with thiopurine drugs. The 
results described in 3.3.4 show that it is also suitable to detect thiopurine 
metabolites in T-ALL derived cells in culture. This method is more sensitive than 
previous methods used to detect meTGMP as this was undetectable in cells 
treated with MP in similar previous cell culture studies (Coulthard et al., 2002) 
but is detectable at low levels by this method. 
Cells grown with 1 mM and 250 µM allopurinol and 10 mM MP do not show the 
increase in the ratio of TGNs to methylated metabolites seen in patients treated 
with a combination of thiopurine and allopurinol (Sparrow et al., 2005; Leung et 
al., 2009; Brackett et al., 2014). There may be several reasons for this. These 
cells are were only grown for 24 hours whereas patient samples are typically 
measured after 12 weeks treatment, possibly changes in metabolite levels are 
dependent on longer term changes in expression of enzymes responsible for 
thiopurine metabolism. Also cultured cells are only one cell type and are not 
RBCs, the cell type in which clinical metabolite measurements are made, or 
hepatocytes, a cell type in which much first-pass thiopurine metabolism takes 
place; therefore these cells may not be capable of producing this effect on 
metabolite levels. 
5.4.2 Parameter estimation of initial model 
Estimating parameters using CoPaSi produced a model which simulated the 
time course of metabolites corresponding to experimental data with the 
constraint that [TXMP] should be at lower concentrations than [TIMP] and 
higher than [TGMP] (Zimm et al., 1985). It also conformed to data showing that 
[TUA] should be lower concentration than [TIMP] at early time points (Kalra et 
al., 2007). The differences between the versions of the model with parameters 
estimated using either the mean of all of the data from cells treated with MP or 
with the separate replicates of the same data showed that the estimation with 
the mean produced a better fit, by the measure of sums of squares, to the data 
used for estimation. This is due to the variability between the separate repeats 
of the data, meaning that fitting all of the data is not possible with a deterministic 
model. Deterministic modelling simulates the outcomes of reactions according 
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to a system of ODEs with the outcome of each reaction being guaranteed for a 
given set of initial conditions. Stochastic modelling uses an estimate of the 
probability of a reaction occurring in order to determine whether or not that 
reaction should progress for each model time-point this results in different 
outcomes each time the model is simulated, therefore hundreds or thousands of 
model simulations are run and the outcome of these assessed. This is a more 
realistic representation of biological reactions that may be unlikely to happen 
and is able to reflect the variability seen in biological data. Given the high level 
of biological variability in this data set it may be appropriate to model this 
system stochastically. 
The results of time course simulations (Figure 5.3) from the two model versions 
were similar in spite of several parameters, such as the Vmax of GMPS, varying 
by 10 or more fold between the two versions. This suggests insensitivity to 
these parameters, however a more formal sensitivity analysis would be useful. 
A sensitivity analysis varies various parameters on the model and then 
measures the magnitude of the effect on model output; parameters which cause 
small changes in output are those with low sensitivity. This would be useful 
information when focussing future studies. Parameters which vary little between 
model variants, indicating that they are possibly sensitive, such as the Km and 
Vmax for HGPRT, the rate of incorporation of TGNs into DNA and the uptake of 
MP into cells may be more important to study in order to improve the model and 
also as they may be key to the metabolism of thiopurines. Given that variation in 
CNTs causes MP resistance (Fotoohi et al., 2006a) it seems reasonable that 
the model parameter representing this reaction is sensitive to changes. It is 
generally held that IMPDH is the rate limiting reaction in the production of GMP 
or TGMP from IMP or TIMP (Magasanik et al., 1957); therefore, it is reasonable 
that the model is likely to be insensitive to the reaction rate of GMPS, a 
subsequent reaction in this pathway.  
5.4.3 The effect of TPMT variation 
The model was able to replicate qualitatively, but not quantatively, the effect of 
increasing TPMT activity on [tDNA] in cells treated with equitoxic doses of MP 
(Coulthard et al., 2002) (Figure 5.4 a). Given that these results were based on 
different cell lines equitoxic doses may not be an appropriate test for the 
accuracy of the model. The model was able to produce qualitatively similar 
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results with a MP to those described at equitoxic doses of 1.8 and 8 µM MP. 
[MeTIMP] increases and [tDNA] levels decrease in cells with high TPMT activity 
compared to normal cells. This suggests that the model is reasonably able to 
replicate other data on increasing TPMT activity. 
The model was also able to qualitatively replicate the effect of lowering TPMT 
activity in Jurkat cells on meMP (Figure 5.4d) (Misdaq et al., 2012), however the 
effect is larger in the model. The effect of lowering TPMT activity on TGN 
concentration in these cells was a non-significant reduction in TGN levels 
(Misdaq et al., 2012). This is surprising given the effect of low TPMT levels in 
patients (Lennard et al., 1997; Appell et al., 2013). This effect is not matched in 
the model, where a large increase in TGN concentration occurs, as would be 
expected from patient data. This suggests that although the model may not 
reproduce the situation in Jurkat cells it may be relevant to other systems. 
TPMT activity is higher in Jurkat cells, which lack MTAP activity, than those with 
increased MTAP activity (Coulthard et al., 2011), and this produced a decrease 
in TGNs in MTAP positive Jurkat cells. MOLT-4 have MTAP activity and 
therefore they would be expected to have lower initial TPMT activity and lower 
normal TGNs possibly causing the effect of decreasing TPMT activity to be 
different, as was seen. It may be more appropriate to compare the effect of 
lowered TPMT in a cell line more similar to MOLT-4s. It may also be useful to 
include the effect of the cofactor S-adenosyl-methionine and its metabolism by 
MTAP in a future version of the model. 
There is not yet either a knock down or induced TPMT system available in 
MOLT-4 cells for a true comparison to be made. The model performs 
reasonably well, compared to currently available cell culture and patient data. 
Given the known differences between the cells in which data for the model 
building was collected and those which produced the data used for model 
testing the effect of cofactors on the reactions of TPMT may be important to the 
effect of TPMT levels on cellular metabolism of thiopurines. The differences 
between the model as it stands and the other available data may indicate areas 
of importance which the model should address. 
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5.4.4 Assessing the potential mechanisms of allopurinol action on MP 
metabolism using model variants 
None of the model variants was able to fit all of the data. The model variants 
which fitted the data best, C and A, both included the competitive inhibition of 
HGPRT by allopurinol (Table 5.3). This is a plausible mechanism given that MP, 
HGPRT’s endogenous substrate HX and allopurinol are all structurally related 
and may therefore be able to bind the active site of HGPRT. Although patient 
data show that HGPRT activity is increased after chronic use of a combination 
of AZA and allopurinol (Seinen et al., 2011), this could be due to increased 
expression of HGPRT to compensate for inhibition by allopurinol. Such an effect 
was not included in the model because the model was designed to address 
changes over shorter time scales. The possibility could be investigated 
experimentally by measuring the protein levels of HGPRT in patients before and 
during treatment with this drug combination. 
Model C does not show a decrease in the ratio of [meTIMP, meTIDP and 
meTITP] to [TGMP, TGDP and TGTP] when treated with allopurinol combined 
with MP. As this was not present in this data this is an accurate reflection of the 
available data. Further experiments with other drug combinations are needed to 
determine if this effect occurs in cell culture cells, possibly with a different 
combination of allopurinol and MP. For this reason model A which includes an 
inhibition of TPMT by TX and shows this effect is less likely to be true for this 
data set. 
Model C shows an increase in TGNs with 100 μM allopurinol and 10 μM MP 
compared to 1 mM allopurinol with 10 μM MP; this matches drug sensitivity data 
from MOLT-4 cells shown in Chapter 2. This was the only model to show this 
effect. All other models had very low TGNs with any allopurinol and this may 
support the predictions that HGPRT inhibition and inhibition of MP uptake by 
allopurinol are important mechanisms for the effects of allopurinol on MP 
metabolism. 
Further data collection is needed to test mechanisms by which allopurinol might 
interact with MP metabolism. The current models suggest that HGPRT inhibition 
by allopurinol and TPMT inhibition by TX may both be important, but that 
inhibition of MP uptake cannot be ruled out as model F (just MP uptake 
inhibition) was the second best-fitted model. It may be possible to fit both the 
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original model and the models with allopurinol better if more metabolites were 
measured. A method for measuring TGN incorporation into DNA by LC-MS/MS 
is under development and this may enable better fitting of reaction parameters 
by establishing how many TGNs are lost by this route. It may also be possible 
to improve the measurement of TX by LC-MS/MS, currently not reported due to 
high background, and therefore establish the excretion of MP by XO and also to 
measure the effect of allopurinol on XO activity. Even with current methods it 
may be possible to distinguish between models by producing data with more 
different combinations of MP and allopurinol, including 10 μM MP with 100 μM 
allopurinol, given that only model C produces simulation results that reflect the 
increase in sensitivity to MP with low-dose allopurinol in MOLT-4 cells. These 
data could either be compared to the current model output or parameter 
estimation could be repeated with new data. 
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5.5 Conclusions 
1. A model of MP metabolism has been produced able to model MP 
metabolism and the effect of TPMT on MP metabolism 
2. This model is unable to definitely show which proposed mechanism of action 
allopurinol has on MP metabolism. It suggests that HGPRT inhibition may be 
important but does not rule out inhibition of MP uptake 
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Chapter 6. Conclusions 
6.1 
Thiopurines are valuable clinical drugs but their cellular and clinical effects are 
dependent on metabolism within the body. Thiopurine metabolism is not a linear 
biochemical pathway and the potential outputs in terms of metabolites with 
distinct mechanisms of toxicity will vary with different expression levels of 
enzymes and different thiopurine drugs and combinations with other drugs. 
Therefore, a systems approach is required to understand how thiopurines affect 
cell behaviour. This was approached by building a model which predicts how 
the concentrations of thiopurine metabolites within cells relate to drug 
combination and dose, and how these change over time. The model was 
developed using MP as the thiopurine drug as this has more complex modes of 
metabolism compared to TG. A T-ALL derived cell line was used to obtain 
quantitative experimental measurements of metabolite concentrations on which 
to base parameter estimates and assess model performance. The model was 
then used to investigate the effect of combining MP with allopurinol, a clinical 
drug which affects thiopurine metabolism but in unexpected ways. 
6.1.2 Drug sensitivity in cell culture (Chapter 2) 
MOLT-4 cells are sensitive to cytotoxicity by the thiopurines AZA and MP, with 
ED 50’s of 6 µM and 3 µM respectively, in agreement with previous literature 
(Fotoohi et al., 2006a). Febuxostat, a non-purine XO inhibitor is mildly cytotoxic 
to MOLT-4, Jurkat MTAP -/- and MTAP +/+ cells. Allopurinol and oxypurinol, 
purine analogue XO inhibitors, are not cytotoxic to MOLT-4 and Jurkat cells.  
High concentrations, around 1 mM of allopurinol reduce the sensitivity of MOLT-
4 cells to MP, increasing the ED 50 from 3.21 µM to 42.23 µM. Lower 
concentrations of allopurinol, 100 µM or 10 µM, slight but not significantly 
increase the sensitivity of MOLT-4 cells to MP.  
6.1.3 Novel LC-MS/MS method for detecting thiopurine metabolites 
(Chapter 3) 
An LC-MS/MS method capable of detecting 11 thiopurine metabolites and 
allopurinol has been developed. It is sensitive and reliable enough to detect 9 
thiopurine metabolites in both RBCs and PBMC from patients. This method 
involves less pre-processing than previously developed methods (Lennard, 
1987; Dervieux and Boulieu, 1998c; Hofmann et al., 2012; De Nicolo et al., 
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2014) this will hopefully reduce variability in results as it has been shown that 
methodological differences are responsible for differences in detection of TGNs 
by different methods (Shipkova et al., 2003). This reduced pre-processing also 
allows detection of the mono, di and tri phosphate forms of TGNs and 
methylated metabolites to be detected individually. This is in contrast to almost 
all previous methods (Lennard, 1987; Dervieux and Boulieu, 1998c; De Nicolo 
et al., 2014), most of which rely on acid hydrolysis or enzymatic digestion to 
remove phosphate groups. These methods produce thioguanosine from a 
combination of all TGNs and me MPR (De Nicolo et al., 2014) or 4-amino-5-
(methylthio)carbonyl imidazole from methylated metabolites (Dervieux and 
Boulieu, 1998c; Dervieux and Boulieu, 1998b). This pooling of metabolites 
reduces the information that can be gained about each sample, whether clinical 
or from cell culture cells. MP and TIMP were also detectable but with slightly 
less reliability than required for a clinical method. The inclusion of MP, TIMP 
and allopurinol makes this method able to detect a greater range of thiopurine 
metabolites and related drugs than previously published methods (Zimm et al., 
1985; Hofmann et al., 2012), although the method described by Zimm et al 
(Zimm et al., 1985) was able to detect TXMP which due to a lack of standard 
this method could not. The ability to measure TXMP would improve estimation 
of model parameters especially those for IMPDH and GMPS. However, this 
method was able to provide quantitative data covering many of the metabolites 
of MP to inform the computational model. Fransson et al. (Fransson et al., 2006; 
Fransson et al., 2007) found that modelling thiopurine metabolism using data for 
only the two usually reported pooled metabolites, thioguanosine and me MPR, 
was difficult therefore this new LC-MS/MS method has been important to the 
success of the computational modelling in this project.  
This method was unable to detect the endogenous purines with adequate 
reliability. Therefore ATP and GTP data were not suitable either for clinical 
samples or for collection of quantitative data for a computational model; this 
restricted the scope of the computational model to thiopurine metabolism alone 
and did not include any interactions with endogenous purine metabolism. 
LC-MS/MS data showed that 1 mM and 250 µM allopurinol reduced the 
concentration of MP metabolites, including TGNs, in cells treated with 10 µM 
MP. This may explain the reduction in sensitivity to MP given that TGN 
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incorporation into DNA is important to cell death following thiopurine treatment 
(Lee and Sartorelli, 1981; Elion et al., 1988; Bohon and de los Santos, 2003). 
6.1.4 Approaches for modelling MP metabolism (Chapter 4 and 5) 
Various approaches to computational modelling of thiopurine metabolism were 
attempted. The initial stages for the development of the model of thiopurine 
metabolism was based on a model of endogenous purine metabolism by Curto 
et al (Curto et al., 1998b). A model combining endogenous purine and 
thiopurine metabolism could not be justified by either previously available data 
or data that was collected using the novel LC-MS/MS method. The novel LC-
MS/MS method did not produce consistent data about endogenous purine 
concentrations. This may be due to natural variation in ATP and GTP levels in 
cells or due to cross-talk from other substances with the same mass and 
chromatographic characteristics. Therefore a model of only MP metabolism was 
built in CoPaSi (Hoops et al., 2006). 
Metabolite measurements taken over 24 hours after 10 µM MP treatment of 
MOLT-4 cells were used to estimate the parameters of this model not 
determined by the literature. This model could qualitatively reproduce the 
effects of TPMT induction on incorporation of TGNs into DNA and levels of 
methylated metabolites compared to previously published data (Coulthard et al., 
2002). These data were from a different cell line to that modelled and so this 
was a good result. A comparison of time course simulation data from the model 
reflecting inhibition of TPMT on TGN and methylated metabolite concentrations 
showed a qualitative match of methylated metabolite concentrations but no 
match for TGNs (Misdaq et al., 2012). Given differences in the cell lines used 
this is not unreasonable, as the cell line in which the data were collected had 
been shown to lack MTAP whilst the cell line modelled does not and this affects 
TPMT activity (Coulthard et al., 2011).  
Overall, this appears to be a successful model of MP metabolism that would be 
suitable for further investigations into the effects of varying activities of enzymes 
of thiopurine metabolites. However, it must be noted that this model has only 
had parameters estimated with data obtained from one cell line, MOLT-4 cells. 
This limits conclusions drawn from the model to this cell line, as has been 
shown by the quantitative differences between the model and previously 
reported data from other cell lines. One potential use of the model is to compare 
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the parameters after re-estimating parameters using data sets from other cell 
lines with different sensitivities to MP. This would allow exploration of how 
thiopurine metabolism affects sensitivity to thiopurines. A similar approach using 
a model of the effects of TGN incorporation by Panetta et al. (Panetta et al., 
2006) explored differences in sensitivity to thiopurines due to cellular response 
to TGN incorporation into DNA. The model does not reflect whole body 
metabolism as it relies on data from only one cell line and does not take 
account of transport of thiopurine drugs and metabolites between 
compartments. This can be seen in the differences between MOLT-4 cell 
chromatograms, and chromatograms of RBCs and PBMCs from a patient 
(Figure 3.2 and Table 3.4). Most strikingly neither cell type from the patient 
shows much TIMP, whereas in MOLT-4 cells this is a very abundant metabolite. 
There is also a difference in the relative abundances of the mono, di and tri 
phosphate forms of the metabolites between both cell types from patients and 
cultured cells.  
The model is also limited in terms of timescale as it uses only data from the first 
24 hours after MP treatment, and, as it does not take account of cell division, 
further testing would be needed to assess the utility of the model beyond this 
time point.  
The model will be useful in complementing the data regarding thiopurine 
metabolism in cell lines already available and will form the basis on which more 
complex models can be developed.  
6.1.5 Mechanism of interaction between allopurinol and MP metabolism 
(Chapter 2 and 5) 
Metabolite measurements after treatment with 1 mM or 250 µM allopurinol in 
combination with 10 µM MP showed lower concentrations of all thiopurine 
metabolites, except for MP, than 10 µM MP alone. This could explain the 
decreased sensitivity to MP of MOLT-4 cells in the presence of high doses of 
allopurinol. By reducing the amount of active metabolites cell death is reduced. 
There was no decrease in the ratio of methylated metabolites to TGNs. This 
suggests that at these particular concentrations of drug and at these time 
points, MOLT-4 cell line data does not reflect clinical data where studies show 
that that allopurinol combined with low doses of AZA or MP reduces the 
concentration of methylated metabolites compared to TGNs (Sparrow et al., 
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2005; Leung et al., 2009; Brackett et al., 2014). However, clinical data from 
patients treated with low dose AZA/allopurinol is generally reported after 12 
weeks of treatment and the thiopurine metabolites are measured in the 
surrogate compartment, the RBCs. Therefore the fact that this effect was not 
observed in cell culture cells over 24 hours, in an enclosed system, is perhaps 
not surprising. 
These metabolite data were used to estimate kinetic parameters of 8 versions 
of the model of MP metabolism and its proposed interactions with allopurinol. 
None of the versions of the model produced fitted much better than any other, 
based on sums of squares assessments of the fit of the models, all of which 
were similar. As discussed below there may be other methods of assessing 
the fit of the data to the various model structures. However the two models 
which performed slightly better than any others both included inhibition of 
HGPRT activity by allopurinol. One of these model variants, C, also produced 
a better fit for TGMP, TGDP and TGTP concentration with 250 μM allopurinol 
with MP. These metabolites are important to the effects of MP therefore the 
ability to fit this particular aspect of the data set may indicate that this model is 
better. A more sophisticated method of weighting the importance of data 
would be likely to improve the discrimination between the models than is 
possible using the default method available in CoPaSi, a mean squares 
method. For example, the application of more formal model selection metrics 
such as Akaike information criterion (Akaike, 1974) which assess across 
whole time course profiles and have the advantage of penalising models with 
large numbers of parameters.  
This indication that allopurinol might inhibit HGPRT may contradict clinical data 
showing increased HGPRT activity with chronic allopurinol and AZA use 
(Seinen et al., 2011). However, the clinically-reported effect could be due to 
transcriptional induction over a longer timescale of HGPRT to compensate for 
lack of activity; such an induction of enzyme expression may not be detected in 
shorter experiments. This effect could be tested experimentally by assessing 
the levels of HGPRT in patient cells before and after treatment with allopurinol 
and AZA or in cultured cells over a longer time. Currently the model variants 
that included allopurinol inhibiting MP uptake into cells cannot be formally 
excluded. The data do not support alterations to the ratio of methylated 
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metabolites to TGNs in short term treatment with high allopurinol compared to 
MP, therefore the model is unable to confirm the inhibition of TPMT by TX seen 
in cell lysate studies (Blakera et al., 2012), however further data need to be 
collected before a concentration dependency of this effect can be ruled out. 
This part of the project has only obtained preliminary results, requiring further 
experimental data for a more accurate model to be produced. However these 
preliminary results suggest interesting lines of future inquiry. 
6.2 Future Work 
6.2.1 Future work on cell culture  
The results showing the effect of relatively high concentrations of allopurinol on 
MP action have only been shown in MOLT-4 cells, and therefore need to be 
confirmed with both lower concentrations of allopurinol and in other cells, e.g. 
Jurkat cells. Currently, to determine if this is a cell line specific, the effect of 
combining AZA and allopurinol is being studied in A549 (lung cancer cells) by 
Dr Sally Coulthard and preliminary results from Mr Joshua O’Hara (Masters 
Student; personal communications) suggest that the efficacy of AZA is reduced 
by high concentrations of allopurinol in A549 cells and that the concentration of 
active metabolites is lower in cells exposed to this treatment. 
In addition to these studies the effect of allopurinol on both AZA and TG 
metabolism should be investigated to confirm if the same phenomenon is 
present, a reduced efficacy with high concentrations of allopurinol and an 
increased efficacy with low concentrations of allopurinol. Investigating the other 
XO inhibitors, febuxostat and oxypurinol, a metabolite of allopurinol, to confirm if 
they also affect thiopurine metabolism would also be useful. If it is found that 
febuxostat has a similar effect to allopurinol when combined with thiopurine this 
may be of particular clinical relevance as some patients suffer from 
hypersensitivity to allopurinol but not febuxostat (Ramasamy et al., 2013). A 
recent clinical paper suggests that febuxostat may also modify thiopurine 
metabolism to increase the proportion of TGNs to methylated inosine 
metabolites (Dore et al., 2014). 
Together all these data would further inform the model to understand the 
mechanism of action of combining XO inhibitors with thiopurines. 
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Allopurinol and oxypurinol are only mildly cytotoxic, and are designed as such, 
therefore ED50 data are not obtainable but determining how much drug would 
be required to inhibit XO activity to 50% would be useful for fixing the inhibition 
constants in the model. This would require the optimisation or development of a 
XO activity assay. 
6.2.2 Future Work on LC-MS/MS 
Ideally more thiopurine metabolites should be measured, for example me MP 
and TX. These were tuned for with the MS, but the fragments initially studied 
produced very high background levels. This can be addressed by selecting and 
optimising the detection of alternative fragments, thus allowing the study of XO 
inhibition as these data would likely improve the models ability to fit a parameter 
to XO activity and also inhibition by allopurinol of XO and potential inhibition of 
TPMT by TX.  
In addition, measuring TUA, the final product of XO metabolism, would also 
help inform future models. However TUA is very insoluble, and could not be 
determined by HPLC, and no LCMS/MS determination was attempted.  
Measuring TXMP would enable the contribution of IMPDH and GMPS to 
thiopurine metabolism to be distinguished. Measurement of TXMP was made by 
HPLC however only a small amount was obtained as a gift (Dr Sofie Haglund) 
and it is not commercially available, therefore this could not be included in the 
LC-MS/MS method.  
Further refinement of the measurement of allopurinol and development of a 
method to measure its metabolite oxypurinol would also be helpful in order to 
investigate further their interaction with thiopurines. 
To increase the accuracy of the computational model it will be important to 
measure TGNs that have been incorporated into DNA with greater sensitivity 
and less pre-processing than with currently available methods, which generally 
include the addition of a flurophore to the TGN in DNA (Coulthard et al.; 
Hogarth et al., 2008) or use a carbon-13 isoform as a standard for 
deoxythioguanosine (Wang and Wang, 2010b). This would enable more specific 
fixing of the rate of incorporation of TGNs into DNA which would allow other 
model parameters to be better fixed. Also this would allow this model to be used 
to investigate the effects of incorporated TGNs in DNA on cytotoxicity. 
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Furthermore improving the method for detecting endogenous purines would 
allow the downstream effects of methylated metabolites to be included in this 
model allowing more investigations into the methods of thiopurine cytotoxicity.  
The ratios of the mono, di and tri phosphates of thiopurines detected in cells 
were variable and therefore the phosphatase and kinase reactions causing this 
were not modelled. Mr Philip Berry and Dr Sally Coulthard are investigating the 
effects of sample processing on this problem. 
Also RBC and PBMC samples from patients and cell culture samples all show 
different metabolite profiles (Figure 3.2). Intercellular transport may be the 
cause of some of these differences (Fang et al., 2010) and it would be 
interesting to model this. To explore these effects a post-doctoral project has 
begun to compare the metabolite profiles in RBCs and PBMCs incubated 
together or separately with MP and to use these data to expand the existing 
model of MP metabolism to a model of whole blood metabolism of MP. 
6.2.3 Future work towards a model combing thiopurine and endogenous 
purine metabolism 
There are several areas of interest in the interactions of thiopurines and 
endogenous purines. For instance, a more detailed exploration of the effects of 
meTIMP on DNPS (Mario et al., 1993). This would require more reliable data 
about the concentrations of endogenous purines before and after treatment with 
thiopurine drug. Comparison of cell growth in HX containing and HX free media 
and the effect of thiopurines on endogenous purine metabolism would help 
shed light on the importance of inhibition of DNPS by thiopurine metabolites.  
MTAP an enzyme involved in adenosine salvage also affects the efficacy of 
thiopurine drugs (Coulthard et al., 2011). In order to improve our understanding 
of these effects the interaction between DNPS and thiopurines would first need 
to be modelled. A model of the spermine pathway including MTAP would be 
useful to gain a deeper understanding of the role of DNPS, this could possibly 
draw on an existing model of polyamine metabolism (Rodríguez-Caso et al., 
2006). Interestingly MTAP also appears to have an effect on TPMT (Coulthard 
et al., 2011) activity and the nature of this effect could be modelled to suggest 
lines of further inquiry. 
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To model the effects of thiopurines on endogenous purine metabolism and vice 
versa detailed data about the interactions between endogenous purines and 
thiopurines with common enzymes is needed. A method using nuclear magnetic 
resonance spectroscopy data to determine kinetic parameters for carbon 
metabolism reactions has recently been described (Eicher et al., 2012) and 
would be very useful to help determine the requisite enzyme activities. 
6.2.4 Future work on the interaction of allopurinol with thiopurine 
metabolism 
The conclusions that could be drawn about the interaction of allopurinol with MP 
were limited; more data need to be collected and a more sophisticated method 
of simultaneously fitting multiple data sets to multiple model structures needs to 
be used to discriminate better between the proposed model structures.  
Metabolite data at other concentrations of MP and different ratios of MP to 
allopurinol could help to better fix the parameters of the proposed models. 
Particularly if the clinical effect of allopurinol on thiopurine metabolism, reduced 
methylated metabolites, is concentration dependent, other ratios and 
concentrations of MP and allopurinol should be investigated. 
TX concentrations in particular, would be useful to improve the fit of the models 
as this would inform the parameters of XO activity and inhibition and also the 
potential effect if TX on TPMT. This could improve the distinction between 
different model variants. 
It may be more appropriate to fit the multiple versions of the model to multiple 
data sets using different software. For example the MatLab extension 
PottersWheel (Maiwald  and Timmer, 2008), which has the facility to perform 
these comparisons directly which CoPaSi (Hoops et al., 2006) does not have. 
PottersWheel would also allow an identifiability analysis to be performed (Hengl 
et al., 2007). Model identifiability describes the extent to which parameters can 
be uniquely assigned given a model structure and the available data, but 
because the model was built in a programme not designed to perform 
identifablity analysis this question has not yet been addressed. However a 
method has recently been published allowing this to be performed in CoPaSi 
although it uses hidden features of CoPaSi (Schaber, 2012). Identifiability 
analysis would allow improved targeting of future data collection experiments. 
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Despite PottersWheel being a more appropriate programme for these tasks it 
was not used during this project as CoPaSi was adequate for the initial phases 
of model building and fitting and although both programmes allow the import 
and export of SBML models they both modify them for use. Due to time 
constraints modifying and revalidating the model in PottersWheel was not 
feasible.  
6.3 Overall conclusion 
A model able to replicate data about the metabolism of MP in cultured cells was 
produced. This model was able replicate the effect of TPMT on MP metabolism 
previously described in the literature.  
A novel method of detecting thiopurine metabolites in cell culture samples and 
patient blood has been developed. 
It has been shown that high concentrations of allopurinol in cultured cells 
reduce the efficacy of MP by reducing the concentrations of active metabolites. 
Low concentrations of allopurinol non-significantly increase the sensitivity of 
MOLT-4 cells to MP, further experiments are needed to determine what effect 
this drug combination has on metabolite concentrations. 
This project has not been able to distinguish the mechanism by which 
allopurinol interacts with MP metabolism by using a computational model. 
However preliminary data from the model suggests that this effect may depend 
on inhibition of HGPRT by allopurinol, an effect not previously seen.  
The model of MP metabolism has given some insights into the clinically relevant 
combination of thiopurine and allopurinol. The model will provide a basis for 
further studies about this and other aspects of MP metabolism. This will benefit 
future patients by better targeting the dosing of this drug. 
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Appendix A 
SBML Model definition of the first model described in Chapter 5 
<?xml version="1.0" encoding="UTF-8"?> 
<!-- Created by COPASI version 4.6 (Build 32) on 2014-09-25 
11:28 with libSBML version 3.4.1. --> 
<sbml xmlns="http://www.sbml.org/sbml/level2/version4" level="2" 
version="4"> 
  <model metaid="COPASI1" id="Model_1" name="New Model"> 
    <annotation> 
      <COPASI xmlns="http://www.copasi.org/static/sbml"> 
        <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
          <rdf:Description rdf:about="#COPASI1"> 
            <dcterms:created> 
              <rdf:Description> 
                <dcterms:W3CDTF>2014-01-
16T15:53:56Z</dcterms:W3CDTF> 
              </rdf:Description> 
            </dcterms:created> 
          </rdf:Description> 
        </rdf:RDF> 
      </COPASI> 
      <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-
syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" 
xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:vCard="http://www.w3.org/2001/vcard-rdf/3.0#" 
xmlns:bqbiol="http://biomodels.net/biology-qualifiers/" 
xmlns:bqmodel="http://biomodels.net/model-qualifiers/"> 
        <rdf:Description rdf:about="#COPASI1"> 
          <dc:creator> 
            <rdf:Bag/> 
          </dc:creator> 
          <dcterms:created rdf:parseType="Resource"> 
            <dcterms:W3CDTF>2014-01-
16T15:53:56Z</dcterms:W3CDTF> 
          </dcterms:created> 
        </rdf:Description> 
      </rdf:RDF> 
    </annotation> 
    <listOfFunctionDefinitions> 
      <functionDefinition id="function_1" name="Henri-Michaelis-
Menten (irreversible)"> 
        <math xmlns="http://www.w3.org/1998/Math/MathML"> 
          <lambda> 
            <bvar> 
              <ci> substrate </ci> 
            </bvar> 
            <bvar> 
              <ci> Km </ci> 
            </bvar> 
            <bvar> 
              <ci> V </ci> 
            </bvar> 
            <apply> 
              <divide/> 
              <apply> 
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                <times/> 
                <ci> V </ci> 
                <ci> substrate </ci> 
              </apply> 
              <apply> 
                <plus/> 
                <ci> Km </ci> 
                <ci> substrate </ci> 
              </apply> 
            </apply> 
          </lambda> 
        </math> 
      </functionDefinition> 
    </listOfFunctionDefinitions> 
    <listOfUnitDefinitions> 
      <unitDefinition id="time"> 
        <listOfUnits> 
          <unit kind="second" multiplier="60"/> 
        </listOfUnits> 
      </unitDefinition> 
      <unitDefinition id="substance"> 
        <listOfUnits> 
          <unit kind="mole" scale="-6"/> 
        </listOfUnits> 
      </unitDefinition> 
    </listOfUnitDefinitions> 
    <listOfCompartments> 
      <compartment metaid="COPASI2" id="compartment_1" 
name="compartment" size="2e-012"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI2"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
26T15:23:41Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </compartment> 
      <compartment metaid="COPASI3" id="compartment_2" 
name="extracellular" size="0.07"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI3"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-05-
08T14:08:30Z</dcterms:W3CDTF> 
                  </rdf:Description> 
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                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </compartment> 
    </listOfCompartments> 
    <listOfSpecies> 
      <species metaid="COPASI4" id="species_1" name="MP" 
compartment="compartment_1" initialConcentration="0"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI4"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
10T10:07:01Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </species> 
      <species metaid="COPASI5" id="species_3" 
name="tGMP_tGDP_tGTP" compartment="compartment_1" 
initialConcentration="0"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI5"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
10T10:05:54Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </species> 
      <species metaid="COPASI6" id="species_4" name="tXMP" 
compartment="compartment_1" initialConcentration="0"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI6"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
10T10:07:25Z</dcterms:W3CDTF> 
                  </rdf:Description> 
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                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </species> 
      <species metaid="COPASI7" id="species_5" name="tIMP" 
compartment="compartment_1" initialConcentration="0"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI7"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
10T10:05:59Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </species> 
      <species metaid="COPASI8" id="species_6" name="tDNA" 
compartment="compartment_1" initialConcentration="0"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI8"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
10T10:05:49Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </species> 
      <species metaid="COPASI9" id="species_7" name="tX" 
compartment="compartment_1" initialConcentration="0"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI9"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
10T10:07:16Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
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          </COPASI> 
        </annotation> 
      </species> 
      <species metaid="COPASI10" id="species_8" name="TUA" 
compartment="compartment_1" initialConcentration="0"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI10"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
10T10:06:03Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </species> 
      <species metaid="COPASI11" id="species_9" name="metIMP" 
compartment="compartment_1" initialConcentration="0"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI11"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
10T10:06:16Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </species> 
      <species metaid="COPASI12" id="species_10" 
name="metGMP_metGDP_metGTP" compartment="compartment_1" 
initialConcentration="0"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI12"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
10T10:06:12Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
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      </species> 
      <species metaid="COPASI13" id="species_11" name="meMP" 
compartment="compartment_1" initialConcentration="0"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI13"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
10T10:06:08Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </species> 
      <species metaid="COPASI14" id="species_12" name="TG" 
compartment="compartment_1" initialConcentration="0"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI14"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
17T14:53:50Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </species> 
      <species metaid="COPASI15" id="species_13" name="TGout" 
compartment="compartment_1" initialConcentration="0"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI15"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
17T13:49:57Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </species> 
      <species metaid="COPASI16" id="species_2" name="MPout" 
compartment="compartment_2" initialConcentration="10"> 
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        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI16"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
10T10:05:44Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
      </species> 
    </listOfSpecies> 
    <listOfReactions> 
      <reaction metaid="COPASI17" id="reaction_1" name="mp 
uptake" reversible="false"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI17"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-01-
16T15:55:12Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
        <listOfReactants> 
          <speciesReference species="species_2"/> 
        </listOfReactants> 
        <listOfProducts> 
          <speciesReference species="species_1"/> 
        </listOfProducts> 
        <kineticLaw> 
          <math xmlns="http://www.w3.org/1998/Math/MathML"> 
            <apply> 
              <ci> function_1 </ci> 
              <ci> species_2 </ci> 
              <ci> Km </ci> 
              <ci> V </ci> 
            </apply> 
          </math> 
          <listOfParameters> 
            <parameter id="Km" name="Km" value="0.121008"/> 
            <parameter id="V" name="V" value="1.79258e-011"/> 
          </listOfParameters> 
        </kineticLaw> 
      </reaction> 
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      <reaction metaid="COPASI18" id="reaction_2" name="HGPRTi" 
reversible="false"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI18"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-01-
16T15:57:46Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
        <listOfReactants> 
          <speciesReference species="species_1"/> 
        </listOfReactants> 
        <listOfProducts> 
          <speciesReference species="species_5"/> 
        </listOfProducts> 
        <kineticLaw> 
          <math xmlns="http://www.w3.org/1998/Math/MathML"> 
            <apply> 
              <times/> 
              <ci> compartment_1 </ci> 
              <apply> 
                <ci> function_1 </ci> 
                <ci> species_1 </ci> 
                <ci> Km </ci> 
                <ci> V </ci> 
              </apply> 
            </apply> 
          </math> 
          <listOfParameters> 
            <parameter id="Km" name="Km" value="548.223"/> 
            <parameter id="V" name="V" value="43.2477"/> 
          </listOfParameters> 
        </kineticLaw> 
      </reaction> 
      <reaction metaid="COPASI19" id="reaction_3" name="IMPDH" 
reversible="false"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI19"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-01-
16T16:01:06Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
150 
 
          </COPASI> 
        </annotation> 
        <listOfReactants> 
          <speciesReference species="species_5"/> 
        </listOfReactants> 
        <listOfProducts> 
          <speciesReference species="species_4"/> 
        </listOfProducts> 
        <kineticLaw> 
          <math xmlns="http://www.w3.org/1998/Math/MathML"> 
            <apply> 
              <times/> 
              <ci> compartment_1 </ci> 
              <apply> 
                <ci> function_1 </ci> 
                <ci> species_5 </ci> 
                <ci> Km </ci> 
                <ci> V </ci> 
              </apply> 
            </apply> 
          </math> 
          <listOfParameters> 
            <parameter id="Km" name="Km" value="4815.39"/> 
            <parameter id="V" name="V" value="20.0001"/> 
          </listOfParameters> 
        </kineticLaw> 
      </reaction> 
      <reaction metaid="COPASI20" id="reaction_4" name="GMPS" 
reversible="false"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI20"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-01-
16T16:03:18Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
        <listOfReactants> 
          <speciesReference species="species_4"/> 
        </listOfReactants> 
        <listOfProducts> 
          <speciesReference species="species_3"/> 
        </listOfProducts> 
        <kineticLaw> 
          <math xmlns="http://www.w3.org/1998/Math/MathML"> 
            <apply> 
              <times/> 
              <ci> compartment_1 </ci> 
              <apply> 
                <ci> function_1 </ci> 
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                <ci> species_4 </ci> 
                <ci> Km </ci> 
                <ci> V </ci> 
              </apply> 
            </apply> 
          </math> 
          <listOfParameters> 
            <parameter id="Km" name="Km" 
value="76855800000000"/> 
            <parameter id="V" name="V" value="353686000000"/> 
          </listOfParameters> 
        </kineticLaw> 
      </reaction> 
      <reaction metaid="COPASI21" id="reaction_5" name="DNA 
incorporation" reversible="false"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI21"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-01-
16T16:06:34Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
        <listOfReactants> 
          <speciesReference species="species_3"/> 
        </listOfReactants> 
        <listOfProducts> 
          <speciesReference species="species_6"/> 
        </listOfProducts> 
        <kineticLaw> 
          <math xmlns="http://www.w3.org/1998/Math/MathML"> 
            <apply> 
              <times/> 
              <ci> compartment_1 </ci> 
              <ci> k1 </ci> 
              <ci> species_3 </ci> 
            </apply> 
          </math> 
          <listOfParameters> 
            <parameter id="k1" name="k1" value="0.0393604"/> 
          </listOfParameters> 
        </kineticLaw> 
      </reaction> 
      <reaction metaid="COPASI22" id="reaction_6" name="XOMP" 
reversible="false"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI22"> 
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                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-01-
16T16:10:51Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
        <listOfReactants> 
          <speciesReference species="species_1"/> 
        </listOfReactants> 
        <listOfProducts> 
          <speciesReference species="species_7"/> 
        </listOfProducts> 
        <kineticLaw> 
          <math xmlns="http://www.w3.org/1998/Math/MathML"> 
            <apply> 
              <times/> 
              <ci> compartment_1 </ci> 
              <apply> 
                <ci> function_1 </ci> 
                <ci> species_1 </ci> 
                <ci> Km </ci> 
                <ci> V </ci> 
              </apply> 
            </apply> 
          </math> 
          <listOfParameters> 
            <parameter id="Km" name="Km" value="2.5"/> 
            <parameter id="V" name="V" value="1.14089"/> 
          </listOfParameters> 
        </kineticLaw> 
      </reaction> 
      <reaction metaid="COPASI23" id="reaction_7" name="XOtX" 
reversible="false"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI23"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-01-
16T16:17:21Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
        <listOfReactants> 
          <speciesReference species="species_7"/> 
        </listOfReactants> 
        <listOfProducts> 
          <speciesReference species="species_8"/> 
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        </listOfProducts> 
        <kineticLaw> 
          <math xmlns="http://www.w3.org/1998/Math/MathML"> 
            <apply> 
              <times/> 
              <ci> compartment_1 </ci> 
              <apply> 
                <ci> function_1 </ci> 
                <ci> species_7 </ci> 
                <ci> Km </ci> 
                <ci> V </ci> 
              </apply> 
            </apply> 
          </math> 
          <listOfParameters> 
            <parameter id="Km" name="Km" value="4.97"/> 
            <parameter id="V" name="V" value="0.366641"/> 
          </listOfParameters> 
        </kineticLaw> 
      </reaction> 
      <reaction metaid="COPASI24" id="reaction_9" 
name="TPMTtIMP" reversible="false"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI24"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-01-
16T16:22:29Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
        <listOfReactants> 
          <speciesReference species="species_5"/> 
        </listOfReactants> 
        <listOfProducts> 
          <speciesReference species="species_9"/> 
        </listOfProducts> 
        <kineticLaw> 
          <math xmlns="http://www.w3.org/1998/Math/MathML"> 
            <apply> 
              <times/> 
              <ci> compartment_1 </ci> 
              <apply> 
                <ci> function_1 </ci> 
                <ci> species_5 </ci> 
                <ci> Km </ci> 
                <ci> V </ci> 
              </apply> 
            </apply> 
          </math> 
          <listOfParameters> 
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            <parameter id="Km" name="Km" value="25.7"/> 
            <parameter id="V" name="V" value="0.0859723"/> 
          </listOfParameters> 
        </kineticLaw> 
      </reaction> 
      <reaction metaid="COPASI25" id="reaction_10" 
name="TPMTtGMP" reversible="false"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI25"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-01-
16T16:27:22Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
        <listOfReactants> 
          <speciesReference species="species_3"/> 
        </listOfReactants> 
        <listOfProducts> 
          <speciesReference species="species_10"/> 
        </listOfProducts> 
        <kineticLaw> 
          <math xmlns="http://www.w3.org/1998/Math/MathML"> 
            <apply> 
              <times/> 
              <ci> compartment_1 </ci> 
              <apply> 
                <ci> function_1 </ci> 
                <ci> species_3 </ci> 
                <ci> Km </ci> 
                <ci> V </ci> 
              </apply> 
            </apply> 
          </math> 
          <listOfParameters> 
            <parameter id="Km" name="Km" value="27.1"/> 
            <parameter id="V" name="V" value="0.00145185"/> 
          </listOfParameters> 
        </kineticLaw> 
      </reaction> 
      <reaction metaid="COPASI26" id="reaction_11" name="TPMTMP" 
reversible="false"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI26"> 
                <dcterms:created> 
                  <rdf:Description> 
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                    <dcterms:W3CDTF>2014-01-
16T16:29:40Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
        <listOfReactants> 
          <speciesReference species="species_1"/> 
        </listOfReactants> 
        <listOfProducts> 
          <speciesReference species="species_11"/> 
        </listOfProducts> 
        <kineticLaw> 
          <math xmlns="http://www.w3.org/1998/Math/MathML"> 
            <apply> 
              <times/> 
              <ci> compartment_1 </ci> 
              <apply> 
                <ci> function_1 </ci> 
                <ci> species_1 </ci> 
                <ci> Km </ci> 
                <ci> V </ci> 
              </apply> 
            </apply> 
          </math> 
          <listOfParameters> 
            <parameter id="Km" name="Km" value="10.6"/> 
            <parameter id="V" name="V" value="9.76512"/> 
          </listOfParameters> 
        </kineticLaw> 
      </reaction> 
      <reaction metaid="COPASI27" id="reaction_8" name="TG 
uptake" reversible="false"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI27"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
17T13:45:15Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
        <listOfReactants> 
          <speciesReference species="species_13"/> 
        </listOfReactants> 
        <listOfProducts> 
          <speciesReference species="species_12"/> 
        </listOfProducts> 
        <kineticLaw> 
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          <math xmlns="http://www.w3.org/1998/Math/MathML"> 
            <apply> 
              <times/> 
              <ci> compartment_1 </ci> 
              <apply> 
                <ci> function_1 </ci> 
                <ci> species_13 </ci> 
                <ci> Km </ci> 
                <ci> V </ci> 
              </apply> 
            </apply> 
          </math> 
          <listOfParameters> 
            <parameter id="Km" name="Km" value="14.21"/> 
            <parameter id="V" name="V" value="0.03343"/> 
          </listOfParameters> 
        </kineticLaw> 
      </reaction> 
      <reaction metaid="COPASI28" id="reaction_12" name="HGPRTg" 
reversible="false"> 
        <annotation> 
          <COPASI xmlns="http://www.copasi.org/static/sbml"> 
            <rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" 
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"> 
              <rdf:Description rdf:about="#COPASI28"> 
                <dcterms:created> 
                  <rdf:Description> 
                    <dcterms:W3CDTF>2014-02-
17T13:46:03Z</dcterms:W3CDTF> 
                  </rdf:Description> 
                </dcterms:created> 
              </rdf:Description> 
            </rdf:RDF> 
          </COPASI> 
        </annotation> 
        <listOfReactants> 
          <speciesReference species="species_12"/> 
        </listOfReactants> 
        <listOfProducts> 
          <speciesReference species="species_3"/> 
        </listOfProducts> 
        <kineticLaw> 
          <math xmlns="http://www.w3.org/1998/Math/MathML"> 
            <apply> 
              <times/> 
              <ci> compartment_1 </ci> 
              <apply> 
                <ci> function_1 </ci> 
                <ci> species_12 </ci> 
                <ci> Km </ci> 
                <ci> V </ci> 
              </apply> 
            </apply> 
          </math> 
          <listOfParameters> 
            <parameter id="Km" name="Km" value="18.8"/> 
            <parameter id="V" name="V" value="0.09"/> 
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          </listOfParameters> 
        </kineticLaw> 
      </reaction> 
    </listOfReactions> 
  </model> 
</sbml> 
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